Archive for May, 2020

This discovery may have clinical importance in management of heart failure.

This discovery may have clinical importance in management of heart failure.Many heart diseases are linked to oxidative stress, an overabundance of reactive oxygen species. The body reacts to reduce oxidative stress where the redox teeter-totter has gone too far up through production of endogenous antioxidants that reduce the reactive oxygen species. This balancing act is called redox homeostasis.

But what happens if the redox teeter-totter goes too far down, creating antioxidative stress, also known as reductive stress? Rajasekaran Namakkal-Soorappan, Ph.D., associate professor in the University of Alabama at Birmingham Department of Pathology, and colleagues have found that reductive stress, or RS/AS, is also pathological. This discovery, they say, may have clinical importance in management of heart failure.

They report that RS causes pathological heart enlargement and diastolic dysfunction in a mouse model. This study, published in the journal Antioxidants and Redox Signaling, was led by Namakkal-Soorappan and Pei Ping, Ph.D., David Geffen School of Medicine at the University of California-Los Angeles.

Antioxidant-based therapeutic approaches for human heart failure should consider a thorough evaluation of antioxidant levels before the treatment, they said. Our findings demonstrate that chronic RS is intolerable and adequate to induce heart failure.

The study used transgenic mice that had upregulated genes for antioxidants in the heart, which increased the amounts of antioxidant proteins and reduced glutathione, creating RS. One mouse line had low upregulation, and one had high upregulation, creating chronic low RS and chronic high RS, respectively, in the hearts of the mice.

The mice with high RS showed pathological heart changes called hypertrophic cardiomyopathy, and had an abnormally high heart ejection fraction and diastolic dysfunction at 6 months of age. Sixty percent of the high-RS mice died by 18 months of age.

The mice with low RS had normal survival rates, but they developed the heart changes at about 15 months of age, suggesting that even moderate RS can lead to irreversible damage in the heart over time.

Giving high-RS mice a chemical that blocked biosynthesis of glutathione, beginning at about 6 weeks of age, prevented RS and rescued the mice from pathological heart changes.

Gobinath Shanmugam, Ph.D., postdoctoral fellow in the UAB Department of Pathology, and Namakkal-Soorappan point out that a 2019 survey found about 77 percent of Americans are consuming dietary supplements every day, and within this group, about 58 percent are consuming antioxidants as multivitamins. Thus, a chronic consumption of antioxidant drugs by any individual without knowing their redox state might result in RS, which can induce pathology and slowly damage the heart.

In a related study, published in the journal Redox Biology, Namakkal-Soorappan looked at the impact of RS on myosatellite cells, which are also known as muscle stem cells. These cells, located near skeletal muscle fibers, are able to regenerate and differentiate into skeletal muscle after acute or chronic muscle injury. The regulation of myosatellite cells is of interest given the loss of skeletal muscle mass during aging or in chronic conditions like diabetes and AIDS.

Recently, Namakkal-Soorappan reported that tilting the redox teeter-totter to oxidative stress impaired regeneration of skeletal muscle. Now, in the Redox Biology paper, he has shown that tilting the redox to RS also causes significant inhibition of muscle satellite cell differentiation.

Rather than genetic manipulation to induce RS, as was done in the heart study, the researchers used the chemical sulforaphane or direct augmentation of intracellular glutathione to induce RS in cultured mouse myoblast cells. Both treatments inhibited myoblast differentiation. Finally, authors attempted to withdraw antioxidative stress by growing cells in medium without sulforaphane, which removes the RS and accelerates the differentiation. Namakkal-Soorappan and colleagues found that a pro-oxidative milieu, through a mild generation of reactive oxygen species, was required for myoblast differentiation.

The researchers also showed that genetic silencing of a negative regulator of the antioxidant genes also inhibited myoblast differentiation.

Co-authors with Namakkal-Soorappan and Ping, and first-author Shanmugam, in the Antioxidants and Redox Signaling study, Reductive stress causes pathological cardiac remodeling and diastolic dysfunction, are Silvio H. Litovsky and Rajesh Kumar Radhakrishnan, UAB Department of Pathology; Ding Wang, UCLA; Sellamuthu S. Gounder, Kevin Whitehead, Sarah Franklin and John R. Hoidal, University of Utah School of Medicine; Jolyn Fernandes and Dean P. Jones, Emory University, Atlanta, Georgia; Thomas W. Kensler, Fred Hutch Cancer Research Center, Seattle, Washington; Louis DellItalia, UAB Department of Medicine; Victor Darley-Usmar, UAB Department of Pathology; and E. Dale Abel, University of Iowa.

In the Redox Biology study, Reductive stress impairs myogenic differentiation, co-authors with Namakkal-Soorappan are Sandeep Balu Shelar, UAB Department of Pathology; Dean P. Jones, Emory University; and John R. Hoidal, University of Utah School of Medicine.

Support for both studies came from National Institutes of Health grants HL118067 and AG042860, American Heart Association grant BGIA 0865015F, the University of Utah, and UAB.

In the two studies, Namakkal-Soorappans name is listed as Namakkal S. Rajasekaran.

See the original post:
Surplus antioxidants are pathogenic for hearts and skeletal muscle - The Mix

Telephone-based genetic counseling is just as useful as in-person meetings for those who would like to better understand and potentially reduce their risks of developing cancer, according to research presented May 13 in advance of the American Society of Clinical Oncology's (ASCO) virtual scientific program, to be held May 29 through 31.

The study indicates that remote forms of counseling, including telephone or real-time video to consult with a healthcare professional, can be a highly effective tool to provide preventive cancer care and genetic counseling, say the authors of the study, which was led by MD Anderson Cancer Center in Houston.

The use of remote healthcare services, ortelehealth, has soared in recent months due to the COVID-19 pandemic and the need for healthcare professionals and patients to find ways to communicate without risking transmission of the coronavirus.

The new study, which was performed prior to the pandemic, was designed to assess ways to make genetic testing more accessible and to validate the process of remote testing and counseling.

The study, dubbed MAGENTA (Making Genetic Testing Accessible)), is a national, randomized trial focusing on people at risk for breast cancer and ovarian cancer. Genetic counseling can be particularly helpful to assess the risks of these two cancers because there are identifiable gene mutations known to increase risk, such as the BRCA gene mutations.

More than a dozen other gene mutations including CHEK2, CDH1, andPTEN mutations are known to increase the risk of breast or ovarian cancer or both.

Genetic counseling and, if indicated, testing can help people understand their risk, determine whether other family members are at an increased risk, and trigger medical care to lower risk, such as more frequent cancer screenings, lifestyle changes, use of preventive medication, and even prophylactic surgery.

The study included nearly 4,000 women age 30 and older who had not had genetic counseling or genetic testing in the past and who either had breast or ovarian cancer themselves or had a family member with one of those cancers.

The participants received a genetic test and were assigned to receive either in-person counseling or telephone counseling. Those who received remote counseling received a genetic home test kit, which required providing a saliva sample in a tube and mailing it in.

Among those participants who completed genetic testing, 7.2 percent were found to have a genetic mutation that increased breast or ovarian cancer risk. Researchers reported no changes in the participants levels of anxiety and distress when receiving remote counseling compared with in-person counseling. In fact, those in the telephone counseling group were more likely to follow through with scheduling related medical care compared with those in the in-person counseling group.

The remote testing and education methods resulted in more follow-through in completing the testing than traditional genetic counseling, even though counseling was provided conveniently by phone, saysEElizabeth M. Swisher, MD, director of the Breast and Ovarian Cancer Prevention Program at the Seattle Cancer Care Alliance and coleader of the Stand Up to Cancer Ovarian CancerNational Ovarian Cancer Coalition Dream Team, which sponsored the study.

Our results provide a foundation for electronic access to testing that goes beyond telehealth access, with equivalent patient outcomes less hassle for patients and less cost to the healthcare system, says Dr. Swisher.

RELATED: COVID-19 Warriors: Stories From the Front Lines of the Pandemic

A randomized, phase 2 clinical trial shows that an approach called transoral resection with low-dose radiation is safe and effective for some people with oropharynx (throat) cancer. The approach is easier to tolerate and leaves patients with fewer long-term side effects related to radiation.

The study of 353 people compared several approaches to throat cancer caused by human papillomavirus, which accounts for about 70 percent of the disease, according to the Centers for Disease Control and Prevention. Researchers examined pathological biomarkers unique to each patient, such as the extent of cancer in the lymph nodes and tumor characteristics.

Following surgery using a transoral robotic approach (TORS), people with a low risk of recurrence were observed. Those with an intermediate risk of recurrence received lower-dose radiation. People at a high risk of recurrence were assigned to the standard dose of radiation plus chemotherapy.

The study showed that for intermediate-risk patients, a reduced dose of radiation after surgery without chemotherapy appears sufficient. Less radiation typically preserves a patients throat function and reduces pain, the authors note.

The group receiving a reduced dose of radiation also had better outcomes than the group receiving high-dose radiation plus chemotherapy. People with low-risk disease had low recurrence rates after two years.

The study showed the value of stratifying patients according to risk and that the TORS surgical approach followed by low-dose radiation is safe and effective in people with intermediate-risk, locally advanced throat cancer, says lead investigator Robert L. Ferris, MD, PhD, director of theHillman Cancer Center at the University of Pittsburgh Medical Center and a surgical oncologist specializing in head and neck cancer.

"These results present a promising deintensification approach," he says.

RELATED: How Will COVID-19 Affect Cancer Research?

About 25 percent of all people with cancer taking oral chemotherapy medications also take herbal supplements, according to research from the University of Rhode Island. Assessing the use of over-the-counter herbal supplements is important because some substances may interact with oral chemotherapy agents, the authors say.

The study of 187 people taking oral chemotherapy drugs found that 24 percent were also taking herbal dietary supplements. The most frequently used supplements were melatonin and marijuana orcannabidiol oil. The authors recommend that people taking oral chemotherapy consult with an oncology pharmacist to prevent drug interactions and maximize the effectiveness of oral chemotherapy.

Federal health officials also recommend that people being treated for cancer consult with their healthcare providers before using any complementary health approach, such as using dietary supplements. According to the National Center for Complementary and Integrative Health, only about 15 percent of people being treated for cancer who use herbal supplements discuss their usage with their healthcare providers.

RELATED: Can You Overdose on Melatonin? How to Determine the Right Dosage for You

The combination of Opdivo (nivolumab) and Yervoy (ipilimumab) with limited chemotherapy appears to prolong overall survival as a first-line treatment for people with metastatic non-small cell lung cancer (NSCLC). The study suggests that adding limited chemotherapy to the combination of Opdivo and Yervoy may reduce the risk of the disease progressing when its in the early stage.

A previous study, CheckMate-227, showed the value of the immunotherapy combination as a first-line treatment for NSCLC. Opdivo is a type of immunotherapy known as a PD-1 inhibitor, while Yervoy is a category of drug known as a CTLA-4 inhibitor.

The new study, called CheckMate-9LA, was designed to assess the value of adding chemotherapy to the combination. The research presented at ASCO is the first release of results from CheckMate-9LA.

The phase 3 trial showed that Opdivo and Yervoy given together with two cycles of chemotherapy reduced the risk of death by 31 percent compared with chemotherapy alone after at least eight months of follow-up. After more than a year of follow-up, the combination plus chemotherapy showed continued improvements in overall survival compared with chemotherapy alone.

Adding a limited course of chemotherapy may help mitigate the risk of early disease progression, saysMartin Reck, MD, PhD, the studys lead investigator and an oncologist at the Lung Clinic Grosshansdorf in Germany. As the data become more mature, I see the potential for an improving survival benefit over time.

RELATED: Smokers Who Quit Before Lung Cancer Diagnosis Are More Likely to Survive the Disease

See the original post:
Genetic Counseling, New Treatments for Lung Cancer and Throat Cancer, and More From ASCO's Annual Meeting - Everyday Health

Magnifier Research has recently published a research report titled Global DTC Genetic Testing Market Size, Status and Forecast 2020-2026 explores the ongoing outlook in global and key regions from the perspective of major players, countries, product types and end industries. The report comprises and forecast values for a versatile understanding. Then, the report offers the perspective of major players, countries, product types and end industries. The research also analyzes top players in the global market and divides the market into several parameters. It presents the profile reviews of the leading participants, their overall market shares in the global DTC Genetic Testing market, business strategies they have adopted, and the latest developments in their respective businesses.

Market Analysis:

The report gives an evaluation of various drivers, technological innovations, upcoming technologies, opportunities, market risks, restraints, market barriers, challenges, trends, competitive landscape, and segments. The report analyzes the scope of different segments and applications that can potentially influence the global DTC Genetic Testing market in the future. Diverse topics discovered in the report includes regional market scope, product-market various applications, market size according to a specific product, sales, and revenue by region, production cost analysis, supply chain, market influencing factors analysis, market size estimates, a look at the target market, an analysis of competition.

DOWNLOAD FREE SAMPLE REPORT: https://www.magnifierresearch.com/report-detail/29799/request-sample

Major key players of the market are: 23andMe, Ancestry, Color, EasyDNA, Family Tree DNAGene by Gene, Full Genomes, Genesis HealthCare, Helix, Identigene, Karmagenes, Living DNA, MapMyGenome, MyHeritage, Pathway Genomics,

For a comprehensive understanding of market dynamics, the market is analyzed across key geographies namely: North America (United States, Canada, Mexico), Asia-Pacific (China, Japan, South Korea, India, Australia, Indonesia, Thailand, Malaysia, Philippines, Vietnam), Europe (Germany, France, UK, Italy, Russia, Rest of Europe), Central & South America (Brazil, Rest of South America), Middle East & Africa (GCC Countries, Turkey, Egypt, South Africa, Rest of Middle East & Africa)

This report segments the global market on the basis of types are:

On the basis of application, the global market is segmented into: Carrier Testing, Predictive Testing, Ancestry and Relationship Testing, Nutrigenomics Testing, Other

Furthermore, the global DTC Genetic Testing research report has mentioned key manufacturers strategic enterprises and provides a brief about their structure. Analysts have also mentioned the research and development conditions of these companies and their provided complete information about their existing products. The report has figured out key factors as per segments and it includes price, value, availability, features, financing, upgrades or returns policies, and customer service. Most noteworthy, this market analysis will help you find market dark spots in the market.

ACCESS FULL REPORT: https://www.magnifierresearch.com/report/global-dtc-genetic-testing-market-size-status-and-29799.html

Projections:

The report offers thoughtful forecasting. It also explains the consumption behaviour of users. Here, analysts have shown real stats and numbers. These bottom-up projections will explain how your marketing and sales efforts will enable you to get a certain percentage of the market. This report study describes the projected growth of the global DTC Genetic Testing market for approaching years from 2020 to 2026.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@magnifierresearch.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Magnifier Research is a leading market intelligence company that sells reports of top publishers in the technology industry. Our extensive research reports cover detailed market assessments that include major technological improvements in the industry. Magnifier Research also specializes in analyzing hi-tech systems and current processing systems in its expertise. We have a team of experts that compile precise research reports and actively advise top companies to improve their existing processes. Our experts have extensive experience in the topics that they cover. Magnifier Research provides you the full spectrum of services related to market research, and corroborate with the clients to increase the revenue stream, and address process gaps.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@magnifierresearch.comWeb: http://www.magnifierresearch.com

Read more here:
COVID-19 IMPACT ON DTC Genetic Testing Market | VOLUME, ANALYSIS, FUTURE PREDICTION, INDUSTRY OVERVIEW AND FORECAST 2026 - Surfacing Magazine

When I left my job in February to focus on trying for a baby, I was full of hope. This was going to be the year Id get pregnant. Instead, Im in limbo, the possibility of becoming a mother seeming further and further away.

My husband Matthew and I have always wanted a family. Weve been together for 11 years, but because wed been teaching abroad, we waited until we moved back to the UK to start trying. In 2017, when we were settled in North Yorkshire and both in our mid-30s, I came off the Pill, but after six months nothing was happening.

My GP told me to enjoy trying to conceive and that everything was fine. But by January 2019 we were worried so had our first IVF consultation. The consultant said my FSH [follicle-stimulating hormone] results were concerning, as were the results of my AMH [anti-Mllerian hormone] test, which confirmed that I didnt have many eggs left. It was the first time we were told there was a problem. I cried all the way home.

We started IVF last May, but my body didnt create enough follicles [ovarian sacs that release eggs for fertilisation] to proceed to the egg-collection phase, so we cancelled the cycle and began again in October. It was a difficult time. The doctors upped my medication and the combination of the hormones and the desire for it to be a success made me anxious. Teaching had been my life, but suddenly it felt like it was getting in the way.

Four eggs were collected, and grew into two embryos. But by the time I was due to have them transferred into my uterus, the embryologist called with awful news: they had stopped growing. I couldnt speak, I just started crying. Matthew and I spent the rest of the day in tears that was our one free NHS cycle.

We looked for a private clinic we could afford, opting for Serum IVF in Athens, which suggested we do two lightly stimulated cycles. The cost, including flights and hotel, came to 6,000, compared to 8,000 back home for just one cycle. On 2 March, we flew to Athens. At the clinic, the doctors spotted a huge polyp in my uterus, so after my egg collection, I had it removed. I later found out that theyd only collected one egg but it was a good one.

After we returned home, we found out that our embryo had developed into a blastocyst, a more advanced embryo of very good quality. It was frozen for use at a later date. I felt calm and positive, and despite coronavirus emerging in Europe, we still thought wed be able to return for our second cycle.

But a few days later the clinic told us it was following strict new guidelines not to proceed with any transfers until further notice. I was in total despair. After two and a half years of trying and getting so close, it had all been taken away. It felt so cruel.

Read more here:
My chances of having a baby are fading away due to coronavirus - Telegraph.co.uk

The test wont tell you other factors that can affect the reproductive system like Endometriosis, Uterine Fibroids, cysts, infections or stress. But it can indicate Polycystic ovarian syndrome (PCOS).

And while the AMH test indicates the number of eggs, it will not deliver the holy grail of fertility information, the QUALITY of eggs. No, the only way to test quality is to fertilize the eggs to see if embryos form. So basically, to make a baby.

If youre not ready for that, the AMH test is at least some information.

Male fertility is so blunt: all the main bits on the outside. A new load of sperm regenerates every 64 days. One explosion in a cup and a fertility specialist has most of the picture.

But a womans fertility is an elusive and complex force of nature. She is with us for a fleeting moment and the further we move into our thirties, the more cryptic she becomes.

My first peek under the veil of my own fertility took three GPs before I was given the AMH test. My result was 11.2. Its in the lower percentile range, but normal for my age. If the results came back abnormally low, theres no question I wouldve reprioritised a baby sooner rather than later.

And if the test does identify a low egg count, its best to know at 28 rather than 35 right?

The cheap, non-invasive AMH test is not subsidised by Medicare, but IVF is. Why fund a last resort fertility procedure but not a simple test that can identify a factor to consider way before IVF is on the table?

Women should be trusted by the medical community to understand the results and not presumed to misuse or misinterpret the information. And this argument should not be used to hold the test back from women like myself just looking for a little more information.

Listen to Before the Bump, Mamamias fertility podcast. Post continues below.

For me, having a normal AMH result didnt make me prioritise a baby but it didnt make me feel less panicked either. Instead, I formed the following logic: if I had a normal egg pool for my age, it was statistically likely Id also take a normal amount of time to fall pregnant.

If I stopped using contraception methods, I anticipated three to six months at least. It could even take a year, I thought.

I wasnt actively trying and I rarely had sex because my fianc worked away. In a calendar year, there were only five months his presence would line-up with my cycle.

And yet, I fell pregnant at the first possible chance after a single night with him. Pregnant with twins.

Read more:
'There's a test to help predict fertility. But at age 34, my GP wouldn't give it to me.' - Mamamia

A NEW promotional body has been set up to bring together the marketing of all types of Mule sheep.

The Mule Group aims to promote the 'adaptability, profitability and ideal mothering characteristics' of females from each of the five main Mule Societies Scotch Mules, North of England Mules, Welsh Mules, Cheviot Mules and Highland Mules.

While each society has always worked as an individual association and will continue to do so, there is a commonality between them in that they all share the same sire in the Bluefaced Leicester and the Bluefaced Leicester Association is supporting the new group to promote the overall message that Mules are the UK's 'Number One commercial breeding female' and ensure marketing of the cross-breds reaches its full potential.

It is estimated that 400,000 mule females are sold annually, with enough breeders involved to give the Mule Group a combined membership of 3500.

Newly appointed chairman of the group, Derek Hall, of the Firth flock, Penicuik, is confident the new initiative will increase demand for both the females and the Bluefaced Leicester breed.

It is important we challenge our competitors and the only way we can do that is to join forces under the one umbrella to promote the attributes of Mules," said Mr Hall. "There is variation in the different types of Mules, however, their key traits of hybrid vigour and mothering ability are all similar.

The message we want to push is that the Mule is adaptable and ultimately ensures profitability to any flock," he said. The Mule is the key link in the sheep industry that brings the hills and uplands, right down to the lowlands together. It is now our challenge to cooperate with each other to ensure the best marketing of the mighty Mule!"

According to Mr Hall, the hybrid vigour of the Mule produces a breeding female that is hardier, with 'amazing' mothering abilities, that can perform well in many different systems.

The hybrid vigour comes from the uniqueness of the Bluefaced Leicester, which is genetically, a different breed of sheep to all others, consequently, the genetics from the Blue provide a higher level of hybrid vigour than any other breed," he asserted. "This in turn ensures a hardy cross-bred female with attributes that outperform that of any other breed or cross."

I am really excited to see where The Mule Group takes us because there is so much room to develop and expand the breeding potential of the Mule and everyone seems to be up for the challenge. Whatever the question, the answer is the Mule!"

See original here:
Mule societies pull together - The Scottish Farmer

More men have died from COVID-19, the disease caused by the novel coronavirus, across the world than women except in Canada.

According to the latest data from the Public Health Agency of Canada, more women have been diagnosed with COVID-19 than men, and more women have died as a result. As of May 15, 55 per cent of confirmed cases of COVID-19 are women, and 45 per cent are men.

Of the total deaths, 53 per cent are women and 47 per cent are men.

READ MORE: How many people is coronavirus really killing? Ontarios data cant tell us

The provinces with the highest number of cases and deaths Quebec and Ontario also have starker gaps between the genders, according to daily provincial epidemiologic summaries.

In Ontario, currently around 57 per cent of those infected are women, while close to 42 per cent are men. Similarly, in Quebec, close to 60 per cent of confirmed COVID-19 cases are women and around 54 per cent of deaths are also women.

This kind of data stands out from other countries who track coronavirus cases, as the vast majority have had more men than women die of COVID-19 since the emergence of the virus, according to Global Health 50/50, an organization out of the UCL Centre for Gender and Global Health in London, England.

Its difficult to discern why women are being more affected by COVID-19 in Canada, but there are several factors that could impact how the virus impacts different genders, says Colin Furness, an epidemiologist at the University of Toronto who specializes in infection control.

One possible reason could be because there are more female residents in Canadas long-term care homes, where the brunt of the cases and deaths in Canada are concentrated, Furness said.

READ MORE: Coronavirus numbers miss some deaths, experts warn. Heres why

Eighty-two per cent of Canadas COVID-19-related deaths have been in nursing homes, according to the National Institute on Aging.

Because of life expectancy differences, you are going to have more women represented in , Furness said, pointing out that Canadian women have higher life expectancies than men.

Data published in 2018 by Statistics Canada found that women were more likely to be widowed than men, and were more likely to be living in a nursing home or seniors residence.

Other countries are not seeing their long-term care homes ravaged by COVID-19 to the extent that Canada has. A study by the International Long-Term Care Policy Network published this month found that compared to 14 other countries, Canada had the most COVID-19-related deaths in long-term care.

Along with a higher representation in nursing homes, women are also more likely to work in caring professions that involve a lot of interaction with other people, Furness said.

This includes jobs like personal support workers (PSWs), like those who work in long-term care homes, he said. A recent study on PSWs in Canada found that workers are largely women and people of colour and/or immigrants.

READ MORE: Canadas lack of race-based COVID-19 data hurting Black Canadians: experts

A report published in February by the Ontario Health Coalition found that Ontario is facing a shortage of PSWs as many leave the profession due to being overworked, underpaid or injured on the job.

Last month, after a second PSW in Ontario died due to COVID-19, the union representing health care workers across the province blamed their deaths due to a lack of available personal protective equipment (PPE).

A report by Global News in April also found that long-term care homes across the country are struggling to access PPE.

Its also important to assess exactly which women are being impacted by COVID-19, said Suzanne Sicchia, an associate professor at the Interdisciplinary Centre for Health and Society at the University of Toronto Scarborough.

If data on race and socioeconomic status is collected, its likely to show women of colour are being disproportionately impacted, she said. More women of colour are employed as personal support workers in Canada, and research has found that people of colour often have worse health outcomes.

Canada should also be collecting data when it comes to the care work women do, personally and professionally, she said.

READ MORE: Coronavirus: 3rd Ontario personal support worker dies from COVID-19

Paid or unpaid, womens care work, for the sick and elderly at home, in their extended family, in their communities, is another possible source of elevated risk of infection, Sicchia said.

Many often think health is shaped by lifestyle choices or genetics, which are important. But its crucial to remember there are a multitude of other factors that shape the health of individuals or populations including income, employment, social status and racism, Sicchia said.

While more women in long-term care along with the number of women working as care providers are factors, its difficult to make concrete assessments without consistent data being collected by governments, Sicchia said.

Undoubtedly there are other determinants at play, and this is why more research and the collection of race-based data and data on other intersecting determinants of health is so important.

Questions about COVID-19? Here are some things you need to know:

Symptomscan include fever, cough and difficulty breathing very similar to a cold or flu. Some people can develop a more severe illness. People most at risk of this include older adults and people with severe chronic medical conditions like heart, lung or kidney disease. If you develop symptoms,contact public health authorities.

Toprevent the virus from spreading, experts recommend frequent handwashing and coughing into your sleeve. They also recommend minimizing contact with others, staying home as much as possible and maintaining a distance of two metres from other people if you go out.

For full COVID-19 coverage from Global News,click here.

2020Global News, a division of Corus Entertainment Inc.

Originally posted here:
More Canadian women have COVID-19 and are dying as a result. Here's some possible reasons why - q107.com

ZUG, Switzerland and CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that four abstracts have been accepted for poster presentation at the American Association for Cancer Research (AACR) Virtual Annual Meeting II, which will take place from June 22 to 24, 2020.

Session information is available online via the Annual Meeting Itinerary Planner through the AACR website at http://www.aacr.org.

Title: Functional and single-cell assessment of CRISPR-modified CAR-T cells from NSCLC patients and healthy donors Session Title: Adoptive Cell Therapy 1 E-Poster Number: 879 Abstract Number: 3338

Title: Allogeneic CAR-T cell products containing 10 gene edits using CRISPR/Cas9 can retain full functionality in vivo and in vitro Session Title: Adoptive Cell Therapy 1 E-Poster Number: 880 Abstract Number: 4647

Title: Allogeneic anti-PTK7 CAR-T cells for the treatment of solid tumors Session Title: Adoptive Cell Therapy 3 E-Poster Number: 3243 Abstract Number: 6231

Title: Targeting T cell lymphomas with CRISPR/Cas9-generated anti-CD70 allogeneic CAR-T cells Session Title: Adoptive Cell Therapy 5 E-Poster Number: 6595 Abstract Number: 3308

About CRISPR Therapeutics CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit http://www.crisprtx.com.

CRISPR Investor Contact: Susan Kim +1 617-307-7503 susan.kim@crisprtx.com

CRISPR Media Contact: Rachel Eides WCG on behalf of CRISPR +1 617-337-4167 reides@wcgworld.com

More here:
CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2020 Annual Meeting - Stockhouse

A gene therapy that eliminates the need for radical cystectomies (complete removal of the bladder) in a particular, aggressive form of bladder cancer is undergoing Priority Review by the U.S. Food and Drug Administration (FDA). It was developed by FKD Therapies Oy with the close collaboration of the Society of Urologic Oncology Clinical Trials Consortium in a novel industry/professional society partnership.

Originally, the therapy nadofaragene firadenovec (rAd-IFN/Syn3), since dubbed INSTILADRIN was developed in the lab of Colin P.N. Dinney, M.D., chairman, department of urology, division of surgery, University of Texas MD Anderson Cancer Center, Houston, and co-founder of the Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), which was critical in conducting the clinical trials.

As Dinney recalled, I developed this drug from preclinical to Phase I with Schering-Plough Corp. Then Schering was bought by Merck, which decided not to develop it.

That was around 2009, when the financial crisis was constraining research budgets and relegating many urologists to procedures.

To ensure that urologists retained awareness of and access to research opportunities, Dinney co-founded SUO-CTC, a network of approximately 400 academic and private practice urologists and 200 clinical sites. It works as an independent partner and consultant with biopharmaceutical companies to identify patients and sites for clinical trials, review clinical trial protocols, and meet with investigators and their collaborators to improve clinical trials.

This early, active involvement enables urologists to identify additional opportunities for companies while also expanding research opportunities for its urologist members. In addition to bladder cancer trials, the SUO-CTC also collaborates in partnership with pharmaceutical and biotechnology companies to develop and conduct trials for prostate cancer and renal cancer.

Its a very lean organization that offers enormous advantages to its pharma partners, Gennady Bratslavsky, M.D., told BioSpace. Its expertise encompasses many urologic sub-specialties including, but not limited to, sequencing and biomarkers, and insights from practicing physicians and academic experts. By providing this expertise early, we become an intellectual partner, which is a unique approach.

The development of nadofaragene firadenovec is a prime example of an effective collaboration between the SUO-CTC and pharma to develop a novel therapeutic that addresses an unmet need for patients with bladder cancer," Bratslavsky said.

When the SUO-CTC was formed, however, it started at ground zero.

We needed a trial to jumpstart the activity of the bladder cancer committee, and I had discussed nadofaragene firadenovec with the president of FKD Therapies Oy, Dinney said.

Not only did Dinney discuss his Phase I data, but he also discussed a particular patient. I had a patient with Alzheimers disease with high-grade non-muscle-invasive bladder cancer who had not responded to BCG therapy. His wife felt surgery was not a good solution because of his Alzheimers, Dinney said. He enrolled the man into a trial, and administered one of the higher doses. He remained disease-free until he died of Alzheimers four years later.

FKD licensed the therapy and Dinney negotiated for the SUO-CTC to have exclusive control of the trial sites. The organization recruited 13 sites from among its members for Phase II trials, and quickly enrolled patients. Larger Phase III trials also were recruited quickly and with favorable results.

"This treatment is truly a game-changer and adds a powerful new intravesical therapy for patients with Bacillus Calmette-Gurin (BCG) unresponsive bladder cancer," Dr. Michael Cookson, president of the Society of Urologic Oncology (SUO), said in a statement.

Specifically, INSTILADRIN is designed for patients with high-grade non-muscle-invasive bladder cancers. The therapy is an adenovirus vector-mediated interferon alfa-2b gene therapy. It was granted Breakthrough Therapy designation by the FDA. Industry watchers say it has the potential to compete with Mercks Keytruda, which was approved in January for the same condition.

Approximately 81,000 people inthe United Statesare diagnosed with bladder cancer every year, according to the American Cancer Society, making it one of the most common cancers. It also is one of the deadliest cancers, claiming nearly 18,000 lives in the U.S. this year alone.

The gene therapy is administered to patients via a catheter, directly into the bladder, once every three months. In trials, it helped the body produce high quantities of a protein that fights the cancer. In the Phase III trial, 53% of patients achieved a complete response as early as three months, and 24% at 12 months. In patients with papillary disease, 73% achieved high-grade recurrence free (HGRF) survival at three months and 44% at 12 months.

INSTILADRIN uses an adenoviral vector to deliver the gene to the cells of the bladder wall, where breaks down and releases its DNA including the interferon gene. That gene is taken into the nucleus and transcribed, ultimately resulting into the secretion of high quantities of interferon alfa-2b proteins being released into the microenvironment of the tumor.

Now, were waiting for approval from the FDA and looking at opportunities to expand indications. Discussions are ongoing, Dinney said. The SUO-CTC also is considering trials to introduce the drug earlier in the course of the disease, as well as including it in combination therapies. His own lab but, as yet, not the SUO-CTC is investigating a companion diagnostic for early applications.

FKD, for its part, led the development, manufacturing and regulatory submission efforts. Assuming the FDA approves INSTILADRIN, FKD plans to license the gene therapy to FerGENE for commercialization in the U.S. and to advance global development.

Here is the original post:
Game-Changing Gene Therapy a Joint Effort by Urologist Consortium and FKD Therapies - BioSpace

Everybody wants to be fit. But not everybody wants to put in the effort to get there.

Who has time to spend long hours at the gym and eating right is such a bore. What if we told you that you could get ripped without exercising and eating whatever you wanted.

RELATED:EXERCISE IS THE BEST WAY TO KEEP THE POUNDS OFF, SAYS NEW STUDY

This is whata team at Washington University in St. Louis medical school achieved with mice in test trials. They created a gene therapy that when given to mice allowed them to build muscle mass and reduce obesity even while eating a diet high in fat and not exercising.

How did it work? The therapytargeted a gene called FST, which makes a protein called follistatin. Follistatin blocks a protein called myostatin, which stops muscle growth to ensure muscles dont get too large.

The researchers injected a virus carrying a healthy FST geneintoeight-week-old mice. They then observed the mice over a period of 18 weeks.

What they found was nothing short of impressive. The mice's muscle mass and strength more than doubled and they experienced reduced damage related to osteoarthritis and less inflammation in their joints.

"Regardless of diet, mice receiving FST gene therapy were protected from post-traumatic OA and bone remodeling induced by joint injury. Together, these findings suggest that FST gene therapy may provide a multifactorial therapeutic approach for injury-induced OA and metabolic inflammation in obesity," wrote the researchers in their paper.

Last but not least, the researchers were worried that the muscle growth caused by the therapy could hurt the heart. However, the study revealed that the heart function and cardiovascular health of treated mice actually improved.

If the therapy can be adapted to work for humans both its appeal and its applications would be limitless. The research was published in Science Advances.

Here is the original post:
New Gene Therapy Promises You Will Get Ripped Without Stepping in a Gym - Interesting Engineering

PHENOMENAL WOMEN SCIENCE & RESEARCH

The San Diego Union-Tribune and the Womens Museum of California are celebrating a century of female achievement in San Diego to mark the 100th year of womens suffrage in America.

The second installment of this series pays tribute to pioneering female scientists and researchers who pushed boundaries in exploring our world and beyond and helped cultivate new generations of curious thinkers.

Spotlighted is Sally Ride, the first U.S. woman in space, who encouraged girls interest in science with her namesake educational program, Sally Ride Science, based at UC San Diego. Here are 11 other women in science and research you should know.

Margaret Burbidge

(U-T file)

A lot of people told Margaret Burbidge she was invading a mans world in the late 1930s when she took her first steps toward becoming an astronomer. She was undeterred even though many key telescopes were off-limits to women. Burbidge pushed through the sexism and became one of the most influential astronomers of her era, largely due to her insights about the chemical composition of stars. Her work helped scientists figure out how stars are made and earned her the nickname Lady Stardust. She also helped to develop the Hubble Space Telescope. And in 1962, she became a founding faculty member at UC San Diego, where she continued research that would later earn her the National Medal of Science. Burbidge died on April 5 at the age of 100.

Karen Nelson

(Howard Lipin/The San Diego Union-Tribune)

Karen Nelson was an early bloomer. At age 7, she joined fellow students in studying how nutrients and sunlight affect the growth of plants. The experiment stoked her interest in science. She went on to become a Cornell-trained physiologist who specializes in the study of the human microbiome the genetic material found in all of the micro-organisms that live in and on our bodies. Nelson led the first group of scientists in publishing the first major paper on the human microbiome. The paper spotlighted an obscure area of research that is now regarded as indispensable to understanding and treating everything from diabetes to multiple sclerosis to depression. Nelson today serves as president of the J. Craig Venter Institute, the renowned research center in La Jolla.

The UC San Diego graduate floated out of an airlock and into history in October as a member of the first all-female team of spacewalkers. The 42 year-old astronaut achieved the fete from the International Space Station, during a six-month mission in which she also conducted research thats meant to help astronauts stay safe and healthy on trips to the moon and Mars. Meir also became a popular host of space-to-Earth broadcast interviews, including an especially poignant one with TV host Stephen Colbert. And she appeared on camera to give earthlings who were sheltering at home from the coronavirus lots of advice about how to live in isolation. Her future could be even brighter she is among the astronauts NASA will consider as crew members for missions to the moon.

Ellen Ochoa

(Cindy Lubke Romero/The San Diego Union-Tribune)

Theres a word that often appears immediately after Ellen Ochoas name: first. In 1991, she became the worlds first Hispanic female astronaut. Two years later, she became the first Hispanic woman to travel in space, streaking into orbit aboard the shuttle Discovery. In 1999, she was a member of the first shuttle crew to dock with the International Space Station. In 2013 Ochoa, who grew up in La Mesa and graduated from San Diego State University, became the first Hispanic to be appointed director of NASAs Johnson Space Center. In 2017, she was inducted into the U.S. Astronaut Hall of Fame. A year later, she retired from NASA, capping a career that spanned nearly three decades.

Maria Goeppert-Mayer

(Evening Tribune)

When it was founded in 1960, UC San Diego quickly hired a handful of renowned professors to signal other faculty that La Jolla was the place to be. The first recruits included Maria Goeppert-Mayer, a German-born theoretical physicist whose discoveries about the nucleus of atoms would help revolutionize everything from weaponry to power generation. Her contribution earned her a share of the 1963 Nobel Prize in physics. She was the first woman in the U.S. to win that prize. The San Diego Union-Tribune responded with a now-infamous headline: S.D. Mother Wins Nobel Physics Prize. Fifty-five years would pass before another woman won the Nobel in physics.

Olivia Graeve

(Courtesy of UC San Diego)

When astronauts return to the moon, they may be flying in a spacecraft made safer by Olivia Graeve. The UC San Diego engineer designs new materials that are meant to withstand extreme environments. She developed and tested an extraordinarily strong type of steel, providing a possible material for everything from spacecraft to body armor. The work occurs at the Cali-Baja Center for Resilient Materials and Systems, which Graeve founded after she became UCSDs first Latina engineering professor. In the summer, the Tijuana native also brings students from Mexico and the U.S. to campus to conduct research, helping cultivate new generations of engineers.

Flossie Wong-Staal

(Koji Sasahara/AP)

Its impossible to count how many lives shes saved, but the number is enormous. Flossie Wong-Staal helped identify the cause of AIDS in 1983 while working at the National Cancer Institute. A short time later, she became the first scientist to clone HIV, then finished mapping the virus genetically. In 1990, Wong-Staal joined the UC San Diego faculty, doing landmark research that has helped fight HIV/AIDS. She also helped turn UCSDs Center for AIDS Research into a research power, and greatly advanced the field of gene therapy. The Chinese-American virologist retired from UCSD in 2002 but has remained active in science and was inducted into the National Womens Hall of Fame in 2019.

Ayana Elizabeth Johnson

(Evan Agostini/Invision/AP)

Not long ago, the wondrous Caribbean island of Barbuda did little to protect its coral reefs and manage its fish populations. Today it does a great deal through programs that Ayana Elizabeth Johnson helped to shape after she earned a doctorate at UC San Diegos Scripps Institution of Oceanography. It was a first step in her rapid rise as an influential voice in sustainable fishing and ocean conservation. Johnson went on to found and lead Ocean Collectiv, a La Jolla conservation consultancy. She also founded the Urban Ocean Lab, a think tank that helps coastal cities. And she played a key role in organizing the 2017 March for Science, which drew more than 1 million participants worldwide.

Balboa Park is so lush its hard to believe it was once a bland patch of land. Many people infused it with life. But none were more important than Kate Sessions, a botanist and horticulturalist who leased part of the park as a growing field in the late 1800s. Sessions planted a variety of trees, ranging from oak to cypress to eucalyptus. She also brought in jacaranda, and helped found the San Diego Floral Association. Her work earned Sessions the nickname Mother of Balboa Park. The honor was about more than beauty. Sessions also studied plants and chronicled how they grew and changed, bringing her worldwide attention in the scientific community. In 1939, the year before she died, the American Genetic Association honored Sessions with the Frank N. Meyer medal, one of the most coveted honors in plant genetics.

Shirley Meng

(David Baillot/UCSD)

Everyone knows that batteries die. But were you aware that they first become sick? Thats the word that Shirley Meng uses to describe what happens when batteries stop holding a charge. It is a poorly understood process. But Meng has been making important discoveries about the phenomenon at UC San Diego, where she is director of the Sustainable Power and Energy Center. Meng, a nano-engineer, specializes in creating new tools and techniques for visualizing, in real-time, whats happening as a battery fails. Her work is meant to improve everything from smartphone service to the range of self-driving cars. Meng who is known as the battery doctor also founded Super 8 Technologies, a company that is developing battery technology that could be used by the military and in space exploration.

Carol Padden

(Sandy Huffaker)

Some linguists used to pointedly question whether American Sign Language, or ASL, is a genuine language. Padden helped establish that ASL is not only legitimate, but that it is a very precise, complex and expressive way of communicating. Padden, who is deaf, has done similar work on Al-Sayyid Bedouin Sign Language. Shes made her contributions as a linguistics researcher and communications professor at UC San Diego. She also is dean of the Division of Social Sciences, UCSDs largest program. In 2010, Padden was honored for her work by being named a MacArthur Genius Fellow. She continues to operate a research lab, something rarely done by high-ranking university administrators.

Sources: UC San Diego, San Diego State University, NASA, J. Craig Venter Institute, Wikipedia, MacArthur Foundation, New York Times, Los Angeles Times, San Diego Union-Tribune

Read the original post:
Phenomenal San Diego women in science and research - The San Diego Union-Tribune

PharmaSphere: Emerging Biotechnologies-Gene Therapy market gives us the acute prediction regarding sales and trends:The current report focuses on the impact of Covid-19 on PharmaSphere: Emerging Biotechnologies-Gene Therapy market industry. This report covers all the important areas like how the key players are enhancing their activities for their survival in the worldwide PharmaSphere: Emerging Biotechnologies-Gene Therapy market business. Graphs and flowcharts are being used for analyzing the information to be acceptable.

Key player focused on this market are: Advantagene, Amarna Therapeutics, AnGes MG, Inc., Applied Genetic Technologies Corporation, AskBio, Avalanche, Bluebird bio, Celladon Corporation, Dimension Therapeutics, American Gene Technologies International Inc,

Download Special samples With the effect of COVID19@: https://www.regalintelligence.com/request-covid19-global-insights/88714

PharmaSphere: Emerging Biotechnologies-Gene Therapy research study depicts the constantly changing trends and growth in the market with valued CAGR (compounded annual growth rate) in their forecast including all the factors responsible for the changed performance, growth evaluation and profitability in the market business.

Key points on which report focuses are:

Providing acute information.

Professional study for the period 2020-2023a.

Details of upstream raw materials, downstream demand and production value.

Market growth factors.

Market segmentation:

Basis of segmentation: Types of products, application and region.

By Type: Type 1, Type 2

Significant PharmaSphere: Emerging Biotechnologies-Gene Therapy application along with their consumption details: Application 1, Application 2

The time period to estimate the market size:

The history year 2015-2019

The base year 2019

Estimated 2020

Forecast 2020-2023a

Segmentation is concerned with the market share, revenue and growth rate etc. The report shows the high growth period of PharmaSphere: Emerging Biotechnologies-Gene Therapy markets and how can the segments grow during the forecast period.

Ask For Discount@ https://www.regalintelligence.com/check-discount/88714

The main objective of PharmaSphere: Emerging Biotechnologies-Gene Therapy market report is future forecasting, determining opportunities, challenges and threats, making suitable business plans, analyzing market competition and getting advantages and helps in decision making.

This report answers to questions like: Growth rate and market size in 2023a.

Effecting factors, opportunities, challenges, threats of the global PharmaSphere: Emerging Biotechnologies-Gene Therapy market. Competing products.

What M&A activity has taken place in past years.

Table of Contents:

Chapter 1 About the PharmaSphere: Emerging Biotechnologies-Gene Therapy Industry

1.1 Industry Definition and Types

1.2 Main Market Activities

1.3 Similar Industries

1.4 Industry at a Glance

Chapter 2 World Market Competition Landscape

2.1 PharmaSphere: Emerging Biotechnologies-Gene Therapy Markets by Regions

Market Revenue (M USD) and Growth Rate 2015-2023a

Sales and Growth Rate 2015-2023a

Major Players Revenue (M USD) in 2020

2.2 World PharmaSphere: Emerging Biotechnologies-Gene Therapy Market by Types

2.3 World PharmaSphere: Emerging Biotechnologies-Gene Therapy Market by Applications

2.4 World PharmaSphere: Emerging Biotechnologies-Gene Therapy Market Analysis

2.4.1 World PharmaSphere: Emerging Biotechnologies-Gene Therapy Market Revenue and Growth Rate 2015-2020

2.4.2 World PharmaSphere: Emerging Biotechnologies-Gene Therapy Market Consumption and Growth rate 2015-2020

2.4.3 World PharmaSphere: Emerging Biotechnologies-Gene Therapy Market Price Analysis 2015-2020

Chapter 3 World PharmaSphere: Emerging Biotechnologies-Gene Therapy Market share

3.1 Major Production Market share by Players

3.2 Major Revenue (M USD) Market share by Players

3.3 Major Production Market share by Regions in 2020, Through 2023a

3.4 Major Revenue (M USD) Market share By Regions in 2020, Through 2023a

Chapter 4 Supply Chain Analysis

4.1 Industry Supply chain Analysis

4.2 Raw material Market Analysis

4.2.1 Raw material Prices Analysis 2015-2020

4.2.2 Raw material Supply Market Analysis

4.2 Manufacturing Equipment Suppliers Analysis

4.3 Production Process Analysis

4.4 Production Cost Structure Benchmarks

4.5 End users Market Analysis

Get Full Report@ https://www.regalintelligence.com/buyNow/88714

Conclusion: This report covers all the necessary information like market landscapes production and consumption analysis, demand and supply analysis, market growth analysis with future predictions and SWOT and PEST analysis, investment and return analysis.

Original post:
PharmaSphere: Emerging Biotechnologies-Gene Therapy Market Current Trends, SWOT Analysis, Strategies, Industry Challenges, Business Overview and...

Logan Howard

Under normal circumstances, graduating seniors gather on Old Campus, clad in zany headwear and surrounded by newly-planted tulips, to partake in the storied traditions that form Class Day. This year, the event was not one day, but seven.The week of reflections and remarks from members of the class of 2020, faculty and alumni culminated with a speech from Jean Bennett 76 on Sunday afternoon.

Seniors received a Class Day care package including tassels, a class anthology and a Yale pin, among other items earlier this week. The Class Day committee, composed of five seniors Sarah Geach 20, Michelle Hu 20, Ananya Indwar 20, Nathan Isaacs 20 and Calvin Schwartzberg 20 encouraged graduates to make masks for their communities rather than the hats that normally characterize the celebration. The past six days have featured remarks from students, faculty members and alumni. On the seventh, Bennett urged graduates to seize the current moment as an opportunity for unity and progress.

We are all now faced with an opportunity for reflection, Bennett said. The world has been so divided, but for once our stress is the same stress something that binds us together.

This terrible experience has created new opportunities and your class will shape things to come. This event will galvanize you all to put your talents, expertise, imagination and passions to good use. You have a huge opportunity to reset to reengineer our world.

Bennett is a professor of ophthalmology at the University of Pennsylvanias Perelman School of Medicine. Her research into retinal diseases led her to develop Luxturna a gene therapy to treat Leber congenital amaurosis, a rare heritable disease that often results in blindness. Luxturna was the first gene therapy ever approved by the Federal Drug Administration for use in humans.

Bennett grew up in New Haven, toured with the Yale Symphony Orchestra in high school and worked in the Universitys biology labs before enrolling as an undergraduate. Reflecting on her time in the Elm City, Bennett recalled anti-Vietnam war movements, the Black Panther trials and a 1:50 ratio of women to men in the sciences.

She drew a connection between researching HIV/AIDS as a Yalie and todays global scientific movement to understand SARS-COV-2.

We do not want to have a future overshadowed by coronavirus, Bennett said. I know that [at] some point we will be able to get back to the projects we put on hold. In the meantime, each of us can try to figure out how to apply our skill the best or to do what we can to contribute.

The Sunday ceremony closed with a performance of Bright College Years by the Yale Bands and Glee Club.

In the days leading up to Bennetts speech, seniors offered their thoughts about the past four years. Joy Qui 20 shared a serious reflection on Tuesday, challenging the idea that all Yale students share fundamental parts of their college experience and the idea that a strong common bond is a positive notion.

The alternative to believing that we share nothing in common would be to believe that Yale is so seductive that four years here is enough to hammer parts of our identities into shapes completely indistinguishable from one another, Qui said.

In a comedic reflection the following day, Simon Fraser 20 and Oscar Lopez 20 congratulated their classmates on something they do all share: the ugliest diploma in America.

We left Yale too early and we had different Yale experiences, Lopez said. Some of us never had the tuna tartar at Harvest.

And some of us still think Shades of Yale is a Facebook group for overhead insults on campus, Fraser responded.

The next several days featured recreations of traditional Old Campus activities such as Vincent Vaughnss 20 Ivy Ode, An Ode to Fight, delivered with an ivy plant in the frame. The class of 2020 will plant their sprig of ivy on Old Campus when it is safe to return. Dean Marvin Chun saluted graduating seniors on their accomplishments, seniors submitted photos and memories from the past four years for a class slideshow and scores of alumni offered a toast to the class of 2020 in video form.

The University is planning to host an in-person celebration of the graduates at a later date.

Mackenzie Hawkins |mackenzie.hawkins@yale.edu

Read the original post:
Virtual Class Week concludes with Bennett's message: You have a huge opportunity to reset - Yale Daily News

Doctors in Southern California are working with researchers in Arizona to better understand the bodys sometimes bizarre immune response to COVID-19 an antibody onslaught that may kill the patient, rather than kill the virus.

The nonprofit Translational Genomics Research Institute (TGen), an affiliate of City of Hope, is peering into specific proteins on the virus to see how they react with different antibodies a high-resolution view that might guide treatment, testing and vaccine development.

The hypothesis is that antibodies can make things worse, and thats whats killing some people, said John Altin, assistant professor in TGens infectious-disease branch. We want to understand how that might be different from an immune response that protects somebody.

As many critically ill patients are treated in clinical trials with convalescent plasma therapy that is, injecting antibodies from recovered COVID-19 patients into those who are very ill, in hopes of triggering protective immune responses its imperative to understand whats behind the differing reactions.

Usually, antibodies provide protection, but there may be a bit of an exception with this virus, Altin said. That is a serious concern.

To that end, TGen and the Center for Gene Therapy at City of Hope are cooperating on a COVID Immunity Study that aims to collect blood from COVID-19 survivors.

The researchers will analyze your blood and profile your immune memory, the study consent form explains.

Participants can use the TGen kit at home. Theyll get a study kit by mail and collect one small spot blood sample, via a finger-prick device, for two consecutive weeks. Then theyll mail the study kit back to TGen.

About 500 people are expected to participate through the course of the study, and researchers may reach out for additional samples, and/or with additional questions, to see how immune memory changes over time.

Participants must be U.S. residents, at least 18 years old, have tested positive for COVID-19, and then recovered. For more information, see https://covidimmunity.org/.

This will help us learn more about how, when and why we produce antibodies in response to a COVID-19 infection, said David Engelthaler, director of TGen North, in a prepared statement. One class of antibodies tackles the infection first, and then another comes in to finish the job. Knowing when these different immune responses occur, and how long they last, could help us understand if some patients gain a certain degree of immunity against reinfection. We need to know how that works.

While large-scale clinical trials involving convalescent plasma are under way all over the nation, this study aims not to treat the disease, but to better understand the mechanisms behind it.

TGen describes its approach as a high-resolution view of the antibody response. It seeks to not only map the viruss proteins in detail, but to also see which parts of those proteins are targeted by antibodies.

Our approach will not only tell you which proteins arebeing targeted, but also be able to tell which regions of each protein are being targeted, Altin said in a statement. Each protein can be recognized by many different types of antibodies. By looking at this level of detail, we then could see elements of the antibody response that others might be missing.

TGen hopes to tease out subtle differences that can help develop therapies, vaccines and better antibody testing.

Others are looking at responses to the entire protein. Our approach is a little different. When we look at the antibody response, we divide it up into thousands of pieces. Theres potential for that to tell us what a beneficial and un-beneficial response might look like, Altin said.

John Zaia, director of the Center for Gene Therapy at City of Hope, is working with TGen, and has other COVID-19-related projects happening as well.

Zaia is leading a research project at City of Hope, in collaboration with Altins lab, that could lead to development of a COVID-19 virus antibody neutralization test, which would quantify antibodies.

Zaia also has received a $750,000 grant from the California Institute for Regenerative Medicine for a clinical study on the use of blood plasma as a potential treatment for COVID-19.

Theyre doing what you could call qualitative and quantitative measurements of the nature of the antibody what does it actually bind to? Zaia said. The virus has this surface protein, the spike protein, but there are also other things the immune system might be seeing. It might be focused on one or more parts of the spike.

The CIRM project will focus on finding plasma donors to determine if theres any correlation between the outcome in the sick patient who received the plasma and the specific antibody that went in. It will focus on under-served areas.

Duarte-based City of Hope was founded in 1913 and is a founding member of the National Comprehensive Cancer Network. It has many sites throughout Southern California, and is investing $1 billion to establish clinics and a cancer center in Orange County. A clinic opened in Newport Beach in January, and a hospital dedicated to cancer treatment and research is slated for Irvine.

On the forefront of science, new discoveries are made every day and so much is still unknown.

I think the FDA said it best: Theres no way that one group could solve all the problems, do all the testing that needs to be done, Zaia said. The whole field is so new.

Theres a balance that must be struck between moving quickly and moving carefully, Altin said. We should know a lot in the next three months about how the antibody response looks, he said. Vaccine development will take much longer.

The rest is here:
Why does immune response to coronavirus save some, kill others? - OCRegister

In wide-ranging congressional testimony, the ousted head of an agency at the center of the federal governments Covid-19 vaccine and treatment response criticized the Trump administration for a slow-footed federal response that could resound throughout the course of the pandemic.

I believe we could have done better, Rick Bright, former chief of the Biomedical Advanced Research and Development Authority (BARDA), told a House subcommittee. We dont have the right leadership for this response and we dont have the right plan for this response.

Bright, who has headed BARDA since 2016, was removed from his post in April. Several days later, he accused HHS of reassigning him because he opposed efforts to put significant funds behind Covid-19 drugs not supported by data, including the anti-malarial hydroxychloroquine. Bright subsequently filed a whistleblower complaint detailing a long history of political interference at the agency, setting up a much-anticipated congressional hearing on Thursday.

Thursday morning, in the leadup to Brights testimony, President Trump dismissed Bright on Twitter as a disgruntled employee who he had never heard of. And HHS released a lengthy rebuttal to the whistleblower complaints, setting the stage for some of the line of questioning Republicans used during the hearing.

Mr. Bright has not yet shownup for work, but continues to collect his $285,010 salary, while using his taxpayer-funded medical leave to work with partisan attorneys who are politicizing the response to COVID-19, a spokesperson said in an emailed statement. His whistleblower complaint is filled with one-sided arguments and misinformation.

The Office of Special Counsel, a government watchdog, however, preliminarily determinedtoday there was evidence backing Brights claims and that he should be reinstated.

Unstrapping a black cloth mask to testify, Bright pointed to mismanagement at HHS from the early days of the pandemic. He said he tried to secure a sample of the virus in January to help expedite the development of vaccines, treatments and diagnostics, but the agency was not able to acquire one until February. He attempted to get funding for vaccines and countermeasures in his first meeting with HHS secretary Alex Azar, he said, but Azar was puzzled by his question, he said, and over the months his continued calls for urgency led to him being shut out.

I was told that my urgings caused a commotion and I was removed from those meetings, Bright said.

He pointed to emails, mentioned from his whistleblower complaint, he received in January from Mike Bowen, the head of mask manufacturer Prestige Ameritech, offering N95s and warning the US had insufficient domestic supply.

He said were in deep shit, the world is, and we need to act and I pushed that forward to the highest levels I could in HHS and got no response, Bright said. From that point I knew we were going to have a crisis.

In their statement, HHS said Bright was not responsible for masks and said Brights assumption that others were not concerned with and working on various workstreams related to COVID-19 preparedness is bizarre and false.

Although Brights complaint pinned his ouster on his opposition to hydroxychloroquine, journalists pointed out that Brights signature was on the documents authorizing the emergency use of the pill for Covid-19 patients. In their statement, HHS called Bright the sponsor of the hydroxychloroquine effort who celebrated when the government was able to secure the supply.

Bright told the House that he had been directed to file those authorizations by the Trump administration. He argued the supply was necessary for clinical trials but not outside it. Alongside other government scientists, he said, he had worked to push back on administration efforts to set up an expanded access protocol by which people including those who hadnt tested positive to Covid-19 could have access to the potentially dangerous drug outside of a hospital. We had to come up with an alternate solution that the administration would accept, he said.

While initially successful, Bright said, he then learned of and spoke out against a subsequent government plan to flood New York and New Jersey with the anti-malarial, leading to his ouster.

That was the straw that broke the camels back, Bright recalled, and expedited my removal.

Turning toward more recent controversy, Bright said a chaotic government response has endangered patients and could impede the response going forward. Over the week-and-a-half since the FDA authorized the use of remdesivir as the first drug shown to have efficacy against Covid-19, doctors have sharply criticized the government for how theyve distributed the Gilead antiviral, with no clear criteria announced and some hospitals with larger numbers of patients unable to secure a supply.

Bright was no longer at BARDA when remdesivir was authorized, but he said no plan had been put in place to prepare for when it was.

There was never action taken on the urgency to come up with a plan for acquisition of limited doses, Bright said, nor to distribute the limited doses of remdesivir.

Now, Bright said, similar problems loom for potential vaccines, once theyre shown to work. Although BARDA and the leading vaccine companies have put significant funds into scaling up manufacturing, an approved vaccine will still come in batches rather than all at once, posing a need to equitably distribute the doses until they are available. Bright revealed that the government had secured access to some of those doses with their funding agreements, but he said theres little plan for how to give them out.

Its going to be a limited supply, Bright said. We need to have a strategy and a plan in place now. We dont have that yet and it is a significant concern.

For a look at all Endpoints News coronavirus stories, check out our special news channel.

Read more:
Rick Bright details mismanaged pandemic response, warns of drugs, vaccine supply problems down the road; HHS pushes back - Endpoints News

The Netherlands is busy adapting in all kinds of ways in order to deal with the corona pandemic. But are our corona measures effective at all? What are the benefits of testing? And why does a vaccine take so long to develop? Biomedical chemist Willem Mulder offers answers to these questions. And he explains how his research is contributing to a solution to the pandemic.

For the past fifteen years, Mulder (43) has been conducting research into nanomaterials that can regulate how the immune system functions. His main focus is on the development of new treatment methods for cardiovascular diseases, cancer, and post-transplant rejection. Although his work can also be applied to many other diseases, including the novel coronavirus. But how can research into new treatments for combatting cancer and carrying out transplants be of any use in the current pandemic? In order to understand this, we need to explain Mulders work method.

Normally Mulder travels back and forth between New York and Eindhoven. In New York, he is Professor of Radiology and Professor of Oncological Sciences at the BioMedical Engineering and Imaging Institute at Icahn School of Medicine at Mount Sinai. In Eindhoven, he works part-time as a professor of Precision Medicine at the Eindhoven University of Technology (TU/e). Furthermore, he is co-founder of Trained Therapeutix Discovery, a company that develops immune therapies which are based on nanomaterials.

On both sides of the ocean, the work of Mulder and his fellow scientists focuses on guiding our immune system to fight diseases. We use nanotechnology to regulate the immune response. Immune cells are produced by stem and precursor cells in the bone marrow. We take control of this production process, so to speak. This allows us to ensure that the immune system achieves whats called a tolerant immune status when the immune system is suppressed. This is very important in organ transplants, for example, so that a patients body will not consequently reject a transplanted organ. The opposite is true for cancer. Then the immune system needs to be intolerant towards a tumor. In these situations, we actually want to trigger immunity, Mulder explains.

Mulders work is best understood when you keep these two scenarios in mind. In one case, you want a patients immune system to have a specific level of tolerance for a transplanted organ. In the other, you want to induce an aggressive immune response against tumor cells. Both scenarios can be applied to many different pathologies, including the novel coronavirus. The regulation of the immune response is crucial when dealing with SARS-CoV-2 infections. A properly functioning immune system can prevent or in case of infection swiftly eradicate the infection. On the other hand, the infection can cause COVID-19 disease in infected patients whose immune system is not functioning adequately. With potentially disastrous consequences. There are plenty of parallels with COVID-19. We see many similarities between hyperinflammation in COVID-19 patients and the immune response after transplants, Mulder continues.

Now, about our immune system. It comprises two parts. The congenital (or non-specific) part is mainly made up of phagocytes. These are cells that can, as it were, eat bacteria, viruses, and fungi. This part of the immune system is our first line of defense and is ready to fight off an invasion of our bodies. When someone has mild symptoms after becoming infected with the coronavirus, that persons natural immune system is perfectly capable of getting rid of the virus.

When the congenital part of the immune system is unable to get rid of an infection, the adaptive part of the immune system takes over the defense task. A virus is made up of a genetic code (RNA) that is packaged in tiny globules of lipids and proteins. Certain types of phagocytes referred to as antigen-presenting cells break down a virus into small molecular fragments called antigens. Cells of the adaptive immune system (lymphocytes) recognize the antigens and are thereby activated. This triggers a cascade of processes that generate a specific immunological memory where antibodies play an important role.

Consequently, those people who experience few issues after infection with SARS-CoV-2 may not be able to build up a high enough level of immunity. When the natural immune system is able to clear the infection itself, there is no strong adaptive immune response needed in order to achieve immunity.

When asked why the elderly in particular are not resistant to COVID-19, Mulder answers: Although it does happen, the amount of young people dying from this virus is statistically negligible. That may be because the immune system doesnt function as well as it should since the number of lymphocytes in the blood declines with age. This is also often the case with people with underlying conditions. For example, the immune systems of people who are overweight, diabetic, or have cardiovascular diseases tend to age much faster. Thats why we suspect that COVID-19 patients with underlying conditions are more susceptible to the disease process spiraling out of control.

Mulder says that it is especially important now to use tests as a means of gaining insight into whether herd immunity is being built up or not. In order to do this, it is essential to know how many people among the population have antibodies. Mulder: Because the only people who have been tested in The Netherlands are those who have had the disease get out of hand, you tend to get a distorted picture. Now it seems as if it is mainly the elderly who are infected. We want to know exactly how the disease progresses in people who have no noticeable symptoms. So far, our policy is based on one-sided data.

In countries where a lot of testing has been done, we see that lots of young people have been infected. From the outset of the crisis, I couldnt understand why no investment was being made into testing on a large scale. It is only then that its actually possible to gain proper insights into how immunity works when it comes to SARS-CoV-2.

Mulder is concerned about the future course of the corona crisis. He emphasizes that the pandemic has just begun. And that we will experience the consequences of the subsequent (economic) damage for a long time to come. Its now just a matter of waiting for a vaccine before we can fully get back to the normal order of the day. As well as a definitively stamp out any new infections. Mulder points out that there are viral infections such as HIV where its never been possible to produce a vaccine. However, he is hopeful that this will succeed for SARS-CoV-2 because it has now been proven that laboratory animals can be vaccinated against the virus.

Making a vaccine is a very complicated and time-consuming process. Mulder explains: A vaccine ensures that you build up immunity and produce antibodies yourself. These antibodies can also be obtained in other ways. One way to do this is to take plasma from people who have been infected and who, as a result, have developed antibodies. Or you could develop antibodies in a lab. The latter has been done by research teams at the Erasmus University in Rotterdam and Utrecht University here in The Netherlands. This type of antibody therapy can certainly provide some relief. However, it is laborious, costly, and difficult to implement on a large scale.

The development of a vaccine takes a long time because it requires a method of getting a pathogen into a person without making that person sick. The pathogen has to be recognized by the immune system in order to trigger an immune response that ultimately provides immunity. Various strategies are possible for achieving this. A vaccine can be based on weakened strains of the pathogen, e.g. by using harmless viruses, by using the genetic code of antigens or by producing the antigens themselves.

The complexity of our immune system makes it extremely difficult to predict which strategy is most likely to succeed. In any event, a considerable amount of time is needed to test the vaccines and produce them on a large scale. Normally, it can take up to 10 years to develop a successful vaccine. Hopefully, that will now happen faster. At the moment, there are about a hundred serious initiatives underway for this at major pharmaceutical companies such as Johnson & Johnson as well as at start-ups and universities, Mulder adds.

Reports have appeared in the media about the use of the malaria medication hydroxychloroquine in the treatment of COVID-19. The immune response to COVID-19 can get out of control with hyperinflammation as a result. Drugs such as hydroxychloroquine may help. Nephrologist Raphal Duivenvoorden of the Radboud University Medical Center (Radboudumc) is researching the effects of this drug on the immune system.

Willem Mulder is also participating in that study. It is a cheap drug with relatively few side effects. However, the timing of the treatment is very important because the immune systems response can worsen the disease. We expect to complete our study this month. Incidentally, there are plenty of medications that are undergoing testing at the moment. Take, for example, those immune therapies that specifically render immune-regulating molecules harmless.

Since the start of the lockdown, The Netherlands has been working hard to make the one-and-a-half-meter society part and parcel of daily life. Some have been critical of the measures introduced by the government and prefer a Swedish corona policy whereby the economy is kept going for the most part.

Mulder understands the decisions made by the Dutch government: Its new territory. We didnt know how the virus would behave or what the long-term effects would be. When you get the flu once in a while, your immune system is quite capable of maintaining a certain level of immunity against new flu strains.

We are born in a situation where both the flu and a certain degree of immunity to it already exists. In contrast, SARS-CoV-2 is completely new. Anyone can get infected. Then it is only logical that strict measures are introduced even when the mortality rate is relatively low. However, its quite difficult to compare countries and regions. Sweden is a sparsely populated country. The Netherlands is not. Population density is also the reason that there are so many infections and deaths in a huge city like New York.

Mulder goes on to add that he finds the introduction of corona measures somewhat worrying: A lockdown was necessary, but I hope it doesnt become the new normal. Governments in the West are now assuming a great deal of power. Freedoms are being taken away from young people while statistically, the problem does not rest with this group. We did what was necessary during the lockdown. I think the quid pro quo answer to this should be that this should not be abused. I hope that people are keeping a watchful eye on this.

More information about nanotechnology can be found here.

Also, check out these animations made by Willem Mulder:

Read more:
Leading scientist Willem Mulder: 'Frequent testing is crucial for predicting immune reactions' - Innovation Origins

During these unprecedented times we are faced with the unique challenge of finding new ways to deliver educational material to our constituents to achieve Texas A&M Agri- Life Extensions vision to Help Texans Better Their Lives. With that we are offering some distance learning opportunities so you can learn more, but in the safety and comfort of your own home.

May 15 Online Beef Cattle and Forage Management Program will be held from 9 a.m.-12 p.m. on May 15. The program, presented by Texas A&M AgriLife Extension Service offices in Atascosa, Bexar, Guadalupe and Wilson counties, will offer one general Texas Department of Agriculture continuing education unit for attendees.

The cost is $10. Attendees will need a laptop or desktop computer and internet access. To register, email Chris Lambert at christopher.lambert@ ag.tamu.edu. Once registered, attendees will be provided the link for participation. Make checks payable to Bexar County Ag and Natural Resources Committee and mail to:

Texas A&M AgriLife Extension Service, 3355 Cherry Ridge, Suite 212, San Antonio, TX 78230.

Program Topics and presenters will be:

COVID-19 and Its Potential Impact on the Cattle Market, David Anderson, Ph.D., AgriLife Extension economist.

Purchasing Replacement Females How to Invest My Dollars, Joe Paschal, Ph.D. AgriLife Extension livestock specialist.

Tips for Getting the Most Return out of Pastures, Josh McGinty, Ph.D., Agri- Life Extension agronomist.

Cost-Saving Tips for Managing Brush, Bob Lyons, Ph.D., AgriLife Extension range specialist.

Biosecurity with Animal Issues During and After a Disaster, Bryan Davis, AgriLife Extension disaster assessment and recovery agent.

May 19 Wildlife Damage Management Series This session will cover Skunks, Coons, Opossumsand More. Presenters are Dr. Maureen Frank and Dr. John Tomecek, Extension Wildlife Specialists. The series will be conducted online from 12-1 p.m. Cost is $10 per session. Checks should be made payable and mailed to Atascosa Wildlife and Fisheries Committee, P.O. Box 379, Leming, Texas 78050. Each session will offer one (1.0) I.P.M. continuing education credit for Private, Commercial and Non-Commercial Applicators. Certificates of completion will be mailed after participant attendance is verified and payment is processed. Please RSVP by the Friday prior to each event by calling 830-569-0034.

Reproduction Management Workshop previously scheduled for May 20 is postponed to October 2020.

Contact the office if you need CEU hours for pesticide applicator license holders.

Continued here:
Atascosa County upcoming events and educational opportunities - Pleasanton Express

DUBLIN--(BUSINESS WIRE)--The "Global Stem Cell Partnering Terms and Agreements 2010-2020" report has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Stem Cell partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Stem Cell agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Stem Cell deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Stem Cell partnering deals.

The report presents financial deal term values for Stem Cell deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Stem Cell partnering field; both the leading deal values and most active Stem Cell dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 600 online deal records of actual Stem Cell deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Stem Cell dealmaking.

A comprehensive series of appendices is provided organized by Stem Cell partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Stem Cell partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Stem Cell technologies and products.

Analyzing actual contract agreements allows assessment of the following:

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/84edx3

Go here to read the rest:
Global Stem Cell Partnering Terms and Agreements 2010-2020 - ResearchAndMarkets.com - Business Wire

People who grew up at high elevations might be less susceptible to the novel coronavirus, according to arecent study of the virus impactin high altitude communities.

The study, which was published by the Respiratory Physiology and Neurobiology journal, compared case data for the virus among communities in Bolivia, Tibet and Ecuador and found that cities and towns in higher elevations have reported fewer COVID-19 cases.

According to BoliviasMinistry of Health websiteLa Paz, Bolivia, has reported 328 cases of the virus and Santa Cruz, Bolivia has reported 2,300 cases as of Friday. La Paz sits 11,943 feet above sea level with a population of 2.7 million people. Santa Cruz is 1,365 feet above sea level with a population of 1.6 million people. For some context, Breckenridge is 9,600 feet above sea level.

This is data that strongly suggests that high altitude is protective, said Dr. Gustavo Zubieta-Calleja, director of the High Altitude Pulmonary and Pathology Institute in La Paz and one of the researchers on the study.

Support Local JournalismDonate

When the virus attacks a persons lungs it causes hypoxia, a term used for oxygen deficiency in the body. Zubieta-Calleja said its similar to taking a person from sea level and putting them at the peak of Mount Everest. People who live at high altitude develop a tolerance to hypoxia and this may help them fight the virus, he said.

To take the theory even further, Zubieta-Calleja suggests a potential treatment for the virus could be to increase a persons red blood cell count at the early stages of the disease to simulate the biology of people who already live at high altitude.

You have to increase the red blood cells for people in order to survive the acute phase, the critical, phase of COVID, he said.

Zubieta-Calleja said a doctor would have to inject the hormone erythropoietin into a persons blood, which would stimulate the production of red blood cells.

That way your red blood cells increase and when things get more severe, then you have a reserve of red blood cells, he said.

However, some doctors are skeptical of studies like this one, because there is still so much researchers dont know about the virus.

Dr. Erik Swenson, a pulmonologist from the University of Washington, said the study shouldnt change how people live their lives in the pandemic.

It could be true, but they dont have the information to really tease out whether this is hypoxia that is living at these altitudes or is it a whole host of other factors that are relevant to those populations, he said.

Swenson suggested the ability to widely test COVID patients in these areas varies and other factors such as low pollution, healthier lifestyles and the dispersion of molecules at high altitude might contribute to the low number of cases in high altitude areas.

One of Zubieta-Callejas previous articles suggests that ultraviolet light can act as a natural disinfectant, which might be a possible reason for why less people have the virus in high altitude areas as well.

Researchers also arent sure how long a person would have to live at high altitude in order to develop the tolerance to hypoxia required to prevent COVID.

Summit County physician Dr. Christine Ebert-Santos said people living at high altitude shouldnt use this information as a reason to stop following protocols that prevent the spread of the disease.

Because of all the other factors involved in this infection, we really cant change anything that were doing, she said. We still have to be just as cautious about the contagious virus (and) the presence of a person who could spread the virus.

Ebert-Santos also said that people come from all over in Summit County and tolerance to hypoxia varies from person to person.

Even though we could say these are potential mitigating factors of COVID infection, we cannot promise any individual that they have more protection or they would have a less severe course, she said.

Follow this link:
People who grew up at high elevation may be less susceptible to COVID-19, according to study - Vail Daily News

Chowhound

If you're experiencing nervousness, racing thoughts, difficulty getting to sleep or even panic during thecoronavirus pandemic, you're not alone. This is astressful time. It's only natural that we'd feel a little amped and uneasy.

If you're having trouble relaxing, avoidingsugarandcaffeineis a must. These ingredients can further stress our bodies and set us up for anxiety. On the flip side, there are foods that can help support our nervous system, increase our resiliency to stress, and even make us feel calm right after we eat them.

As we move through this crazy time, let's lean on these nine foods that promote relaxation.

A fermented drink that falls somewhere betweenyogurtand milk,kefiris a great addition to your social distancing routine. It can be made from dairy milk ornut milkand contains high amounts of beneficial bacteria, which support a healthy gut microbiome. At first glance, our gut health might seem unrelated to our nervous systems, but it's actually quite the opposite. Studies have shown not only thatstress can alter the microbiomein undesirable ways, but thatanxiety could actually be alleviatedby regulating gut bacteria.

You can drink kefir plain or use it as a creamy base for recipes like in thischilled avocado, cucumber and kefirsoup recipe by Julie Smolyansky.

Fatty fish such assalmonare full of omega-3 fatty acids, which have proven to be extremely beneficial for calming the nervous system. In fact, a systematic review of 19 clinical trials -- published inJAMA Open Network--showed that improvements in anxiety symptoms were associated with omega-3 fatty acid treatment. Try thismaple mustard grilled salmon recipefrom Christine Gallary and add salmon to the menu a few times a week.

Read more:The best places to buy fresh seafood online

Tart cherriescontain high levels of various phytochemicals, including melatonin. You've probably heard of melatonin before; it's known as the "sleep hormone" because our bodies release it in the evening to help us get to sleep. Well,studies have shownthat consuming tart cherry juice increases melatonin levels and can improve sleep quality and duration. If you're having trouble winding down at night, tart cherries might be the perfect food to lean on.

Read more:Other foods that can help you sleep

Have you ever wondered whycucumber wateris so popular? It could be because the smell ofcucumbershas natural stress-relieving properties. And it's not only the smell, either. This low-sugar fruit also contains B vitamins, which help support our central nervous system. In fact,studieshave shown that a B complex vitamin can improve anxiety symptoms compared to placebo.

Plenty of studies have found interesting links between vitamin C and mood. In fact, one study on 42 high school students showed thatvitamin C actually lowered anxiety levels. Citrus fruits -- which includelemons,limes, oranges and grapefruit -- are one of the best ways to get vitamin C in your diet. Here'show to segment citrusfor easy, mess-free eating.

You might not think of Vegemite as a health food, buta study, published in 2018, showed that people who consume yeast-based spreads -- such asMarmite, Vegemite, Promite and Aussiemite -- have lower levels of anxiety and stress. According to the researchers, the B vitamin content in these spreads is likely to thank for their anxiety-reducing powers. To start using Vegemite, try spreading it thinly on one side of agrilled cheese sandwich. It adds a bitter, salty flavor that you may just learn to love.

Onionsare one of the best sources ofprebiotic fiber, which helps to feed healthy gut bacteria. As we now know, a balanced microbiome is essential for optimal mental health. Other sources of prebiotic fiber include leeks,bananas,garlicandapples. Try adding raw onions to salads or whips of thisEasy Caramelized Onions recipefrom Aida Mollenkamp.

Pumpkin seedsare one of the best sources of magnesium, which is often referred to as the "relaxation" mineral and is one of the topstress-relieving nutrients. Many of us are deficient in magnesium, as processed foods are virtually devoid of it. But luckily, pumpkin seeds provide more than 150 mg of magnesium per cup, which is almost 50% of your daily recommended intake. Try thishomemade pumpkin seed milk recipe, from the book Magnesium Everyday Secrets.

Lucky you: Research published in theJournal of Proteome Researchfound that eating about 1 and a half ounces ofdark chocolateper day can actually lead to lower levels of cortisol, which is one of our primary stress hormones. For extra relaxation benefits, dark chocolate also contains significant levels of magnesium. Just make sure you opt for dark chocolate and if you're not sure what to buy, these are thebest dark chocolate barsout there.

Focusing on these foods can help promote relaxation, peaceful sleep, and a sense of calm despite what's going on outside. Luckily, most of these foods are also affordable, delicious and can be prepared in any number of creative ways.

The information contained in this article is for educational and informational purposes only and is not intended as health or medical advice. Always consult a physician or other qualified health provider regarding any questions you may have about a medical condition or health objectives.

Link:
9 foods that promote relaxation to help you keep calm - CNET

Sean Doolittle has a lot to say about MLBs plans to return to action, but how do his concerns align with the leagues?Illustration: Eric Barrow (Getty)

While there are certainly many miles of financial sparring between MLB owners and players to get through before the league can return to play, issues rooted in the players concerns over safety. While a good portion, if not all, being the players anger over the owners reneging on a deal they made in March to pay prorated salaries is simply the owners acting like jagoffs, the players have contended that the owners financial risk is matched or exceeded by the players physical one. Today The Athletics Ken Rosenthal and Evan Dreilich got hold of the 67-page memo that outlines how MLB will handle the physical risk and testing to get the season under way.

It covers most everything you would think, while not going into detail about some other things you would hope for. At least not yet. Sean Doolittle outlined what his concerns were a week ago, and it seems a pretty fair checklist for what MLB is proposing to get players back into uniform. To wit:

What Rosenthal and Dreilich have outlined does not address what MLB will do about long-term effects or ailments due to anyone contracting COVID-19. That of course is something that MLB can address when it comes up, as someone is likely going to test positive. But it would also do the players faith some good to have some sort of plan now for long-term care and effects. Theres enough mistrust as is. And no, certainly infertility and hormone ratios arent addressed either, and you can bet a fair amount of players want to ask but are afraid to. Its a major question, as even a mild case could cause a players career to be in severe jeopardy if those long term lung-scarring conditions occur.

G/O Media may get a commission

This is addressed. At least the spring training portion protocol calls for multiple locker rooms, and as many facilities outside as possible. With stadiums remaining empty there are certainly more options than before to be repurposed for this. You could easily envision even stadium concourses that will have no need to house fans used for this. In addition theres a pretty stiff regiment of cleaning and disinfecting for each clubhouse. Spring training, at least to start, will be staggered as to how many players there are at once.

A curious aspect is that for spring training, if teams are going to use their home stadiums and not Florida or Arizona bases, they are encouraged to find minor league or college stadiums to spread out players. But that also means another facility that has to be regularly cleaned and sanitized, as well as testing for additional staff who have to man that venue. This one feels like its probably not going into the final agreement.

This is the meat of what Rosenthal and Dreilich have reported. Players will be tested multiple times per week, and will have an intake screening for spring training wherever that takes place. Players will be tested upon arriving at spring training, and then isolate while awaiting results. The idea here is to start spring training with a clean slate as it were, and to separate anyone who tests positive from jump street. Of course, false positives and negatives will make that nearly an impossibility, but thats the nature of the beast here.

Players will have temperature and symptom checks twice daily at the facilities, as well as be expected to conduct daily temperature tests at home. Any abnormality there will result in rapid-result testing for that individual.

Another concern of many players is the well-being of their families, and thats addressed in that the testing sites for players at their ballparks will be available to players families and area health care workers and first responders. Nothing is mentioned about what happens if a family member of a player tests positive, but one would have to think that a player would have to be quarantined, along with anyone he came into contact with. Of course, that could be a good chunk of or even the entire team.

As far as the amount of testing, spreading it out to the ballpark sites at least pushes it into the neighborhood of doable. A rough estimate of players, coaches, clubhouse staff, stadium staff is about 100 per team. A couple of tests per week for everyone still would be about 800-1,000 per month, which shouldnt deprive cities of tests to people who really need them.

There doesnt seem to be much mention of these folks, which seems to leave it up to the airlines or hotels or bus companies they work for to make sure they get tested. MLB will have to address what kind of assurances are going in both directions for this to work.

MLBs outline here is pretty strict, in that anyone even with a raised temperature wont be allowed on site and will remotely receive treatment from the team physician. The team physician will also direct anyone else who needs to be tested and isolated, as well. Perhaps the size of the roster is meant to address this, but its not a hard leap to envision a team having to keep eight or 10 players in quarantine for two weeks of the season with just one positive test or even one suspicion of infection with a raised temp. And Doolittle is right, and its not addressed yet, is what everyone is going to feel if just one player or team employee becomes dangerously ill. Not just for fear of the virus spreading, but MLB having to answer the question as to why it thought a baseball season was worth having if it meant possibly killing even one person.

Doolittles other concerns about players with compromised immune systems or long-standing conditions, as well as family members such as his own wife, basically are addressed in the rigorous and thorough testing and monitoring outlined here. The hope is that all of it will quickly weed out those that have the virus and keep them from the players and staff that are in more danger than most. But obviously, no system is perfect.

See more here:
MLB'S Testing Plan Is Thorough, But Does It Pass The Doolittle Test? - Deadspin

Los Angeles, United StatesThe report offers an all-inclusive and accurate research study on the global CRISPR And CRISPR-Associated (Cas) Genes market while chiefly focusing on current and historical market scenarios. Stakeholders, market players, investors, and other market participants can significantly benefit from the thorough market analysis provided in the report. The authors of the report have compiled a detailed study on crucial market dynamics, including growth drivers, restraints, and opportunities. This study will help market participants to get a good understanding of future development of the global CRISPR And CRISPR-Associated (Cas) Genes market. The report also focuses on market taxonomy, regional analysis, opportunity assessment, and vendor analysis to help with comprehensive evaluation of the global CRISPR And CRISPR-Associated (Cas) Genes market.

Key companies operating in the global CRISPR And CRISPR-Associated (Cas) Genes market include : , Caribou Biosciences, Addgene, CRISPR THERAPEUTICS, Merck KGaA, Mirus Bio LLC, Editas Medicine, Takara Bio USA, Thermo Fisher Scientific, Horizon Discovery Group, Intellia Therapeutics, GE Healthcare Dharmacon CRISPR And CRISPR-Associated (Cas) Genes

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1704011/covid-19-impact-on-global-crispr-and-crispr-associated-cas-genes-market

Segment Analysis

The segmental analysis will help companies to focus on high-growth areas of the global CRISPR And CRISPR-Associated (Cas) Genes market. In order to broaden the overall understanding of the global CRISPR And CRISPR-Associated (Cas) Genes industry, the report has segregated the global CRISPR And CRISPR-Associated (Cas) Genes business into varied segments comprising product type, application, and end user. This examination has been carried out based on parameters like size, CAGR, share, production, and consumption. Also, region-wise assessment, wherein lucrative prospects that a region or country is likely to offer has been explored.

Global CRISPR And CRISPR-Associated (Cas) Genes Market Segment By Type:

, Genome Editing, Genetic engineering, gRNA Database/Gene Librar, CRISPR Plasmid, Human Stem Cells, Genetically Modified Organisms/Crops, Cell Line Engineering CRISPR And CRISPR-Associated (Cas) Genes

Global CRISPR And CRISPR-Associated (Cas) Genes Market Segment By Application:

, Genome Editing, Genetic engineering, gRNA Database/Gene Librar, CRISPR Plasmid, Human Stem Cells, Genetically Modified Organisms/Crops, Cell Line Engineering CRISPR And CRISPR-Associated (Cas) Genes

Competitive Landscape:

It is important for every market participant to be familiar with the competitive scenario in the global CRISPR And CRISPR-Associated (Cas) Genes industry. In order to fulfill the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global CRISPR And CRISPR-Associated (Cas) Genes market include : , Caribou Biosciences, Addgene, CRISPR THERAPEUTICS, Merck KGaA, Mirus Bio LLC, Editas Medicine, Takara Bio USA, Thermo Fisher Scientific, Horizon Discovery Group, Intellia Therapeutics, GE Healthcare Dharmacon CRISPR And CRISPR-Associated (Cas) Genes

Key Questions Answered

Enquire for Customization in this Report: https://www.qyresearch.com/customize-request/form/1704011/covid-19-impact-on-global-crispr-and-crispr-associated-cas-genes-market

Table of Contents

1 Study Coverage1.1 CRISPR And CRISPR-Associated (Cas) Genes Product Introduction1.2 Market Segments1.3 Key CRISPR And CRISPR-Associated (Cas) Genes Manufacturers Covered: Ranking by Revenue1.4 Market by Type1.4.1 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size Growth Rate by Type1.4.2 Genome Editing1.4.3 Genetic engineering1.4.4 gRNA Database/Gene Librar1.4.5 CRISPR Plasmid1.4.6 Human Stem Cells1.4.7 Genetically Modified Organisms/Crops1.4.8 Cell Line Engineering1.5 Market by Application1.5.1 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size Growth Rate by Application1.5.2 Biotechnology Companies1.5.3 Pharmaceutical Companies1.5.4 Academic Institutes1.5.5 Research and Development Institutes1.6 Coronavirus Disease 2019 (Covid-19): CRISPR And CRISPR-Associated (Cas) Genes Industry Impact1.6.1 How the Covid-19 is Affecting the CRISPR And CRISPR-Associated (Cas) Genes Industry

1.6.1.1 CRISPR And CRISPR-Associated (Cas) Genes Business Impact Assessment Covid-19

1.6.1.2 Supply Chain Challenges

1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products1.6.2 Market Trends and CRISPR And CRISPR-Associated (Cas) Genes Potential Opportunities in the COVID-19 Landscape1.6.3 Measures / Proposal against Covid-19

1.6.3.1 Government Measures to Combat Covid-19 Impact

1.6.3.2 Proposal for CRISPR And CRISPR-Associated (Cas) Genes Players to Combat Covid-19 Impact1.7 Study Objectives1.8 Years Considered 2 Executive Summary2.1 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size Estimates and Forecasts2.1.1 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue 2015-20262.1.2 Global CRISPR And CRISPR-Associated (Cas) Genes Sales 2015-20262.2 CRISPR And CRISPR-Associated (Cas) Genes Market Size by Region: 2020 Versus 20262.2.1 Global CRISPR And CRISPR-Associated (Cas) Genes Retrospective Market Scenario in Sales by Region: 2015-20202.2.2 Global CRISPR And CRISPR-Associated (Cas) Genes Retrospective Market Scenario in Revenue by Region: 2015-2020 3 Global CRISPR And CRISPR-Associated (Cas) Genes Competitor Landscape by Players3.1 CRISPR And CRISPR-Associated (Cas) Genes Sales by Manufacturers3.1.1 CRISPR And CRISPR-Associated (Cas) Genes Sales by Manufacturers (2015-2020)3.1.2 CRISPR And CRISPR-Associated (Cas) Genes Sales Market Share by Manufacturers (2015-2020)3.2 CRISPR And CRISPR-Associated (Cas) Genes Revenue by Manufacturers3.2.1 CRISPR And CRISPR-Associated (Cas) Genes Revenue by Manufacturers (2015-2020)3.2.2 CRISPR And CRISPR-Associated (Cas) Genes Revenue Share by Manufacturers (2015-2020)3.2.3 Global CRISPR And CRISPR-Associated (Cas) Genes Market Concentration Ratio (CR5 and HHI) (2015-2020)3.2.4 Global Top 10 and Top 5 Companies by CRISPR And CRISPR-Associated (Cas) Genes Revenue in 20193.2.5 Global CRISPR And CRISPR-Associated (Cas) Genes Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 CRISPR And CRISPR-Associated (Cas) Genes Price by Manufacturers3.4 CRISPR And CRISPR-Associated (Cas) Genes Manufacturing Base Distribution, Product Types3.4.1 CRISPR And CRISPR-Associated (Cas) Genes Manufacturers Manufacturing Base Distribution, Headquarters3.4.2 Manufacturers CRISPR And CRISPR-Associated (Cas) Genes Product Type3.4.3 Date of International Manufacturers Enter into CRISPR And CRISPR-Associated (Cas) Genes Market3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size by Type (2015-2020)4.1.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales by Type (2015-2020)4.1.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue by Type (2015-2020)4.1.3 CRISPR And CRISPR-Associated (Cas) Genes Average Selling Price (ASP) by Type (2015-2026)4.2 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast by Type (2021-2026)4.2.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast by Type (2021-2026)4.2.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast by Type (2021-2026)4.2.3 CRISPR And CRISPR-Associated (Cas) Genes Average Selling Price (ASP) Forecast by Type (2021-2026)4.3 Global CRISPR And CRISPR-Associated (Cas) Genes Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Breakdown Data by Application (2015-2026)5.1 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size by Application (2015-2020)5.1.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales by Application (2015-2020)5.1.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue by Application (2015-2020)5.1.3 CRISPR And CRISPR-Associated (Cas) Genes Price by Application (2015-2020)5.2 CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast by Application (2021-2026)5.2.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast by Application (2021-2026)5.2.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast by Application (2021-2026)5.2.3 Global CRISPR And CRISPR-Associated (Cas) Genes Price Forecast by Application (2021-2026) 6 North America6.1 North America CRISPR And CRISPR-Associated (Cas) Genes by Country6.1.1 North America CRISPR And CRISPR-Associated (Cas) Genes Sales by Country6.1.2 North America CRISPR And CRISPR-Associated (Cas) Genes Revenue by Country6.1.3 U.S.6.1.4 Canada6.2 North America CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Type6.3 North America CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Application 7 Europe7.1 Europe CRISPR And CRISPR-Associated (Cas) Genes by Country7.1.1 Europe CRISPR And CRISPR-Associated (Cas) Genes Sales by Country7.1.2 Europe CRISPR And CRISPR-Associated (Cas) Genes Revenue by Country7.1.3 Germany7.1.4 France7.1.5 U.K.7.1.6 Italy7.1.7 Russia7.2 Europe CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Type7.3 Europe CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Application 8 Asia Pacific8.1 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes by Region8.1.1 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Sales by Region8.1.2 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Revenue by Region8.1.3 China8.1.4 Japan8.1.5 South Korea8.1.6 India8.1.7 Australia8.1.8 Taiwan8.1.9 Indonesia8.1.10 Thailand8.1.11 Malaysia8.1.12 Philippines8.1.13 Vietnam8.2 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Type8.3 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Application 9 Latin America9.1 Latin America CRISPR And CRISPR-Associated (Cas) Genes by Country9.1.1 Latin America CRISPR And CRISPR-Associated (Cas) Genes Sales by Country9.1.2 Latin America CRISPR And CRISPR-Associated (Cas) Genes Revenue by Country9.1.3 Mexico9.1.4 Brazil9.1.5 Argentina9.2 Central & South America CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Type9.3 Central & South America CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Application 10 Middle East and Africa10.1 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes by Country10.1.1 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Sales by Country10.1.2 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Revenue by Country10.1.3 Turkey10.1.4 Saudi Arabia10.1.5 UAE10.2 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Type10.3 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Market Facts & Figures by Application 11 Company Profiles11.1 Caribou Biosciences11.1.1 Caribou Biosciences Corporation Information11.1.2 Caribou Biosciences Description, Business Overview and Total Revenue11.1.3 Caribou Biosciences Sales, Revenue and Gross Margin (2015-2020)11.1.4 Caribou Biosciences CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.1.5 Caribou Biosciences Recent Development11.2 Addgene11.2.1 Addgene Corporation Information11.2.2 Addgene Description, Business Overview and Total Revenue11.2.3 Addgene Sales, Revenue and Gross Margin (2015-2020)11.2.4 Addgene CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.2.5 Addgene Recent Development11.3 CRISPR THERAPEUTICS11.3.1 CRISPR THERAPEUTICS Corporation Information11.3.2 CRISPR THERAPEUTICS Description, Business Overview and Total Revenue11.3.3 CRISPR THERAPEUTICS Sales, Revenue and Gross Margin (2015-2020)11.3.4 CRISPR THERAPEUTICS CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.3.5 CRISPR THERAPEUTICS Recent Development11.4 Merck KGaA11.4.1 Merck KGaA Corporation Information11.4.2 Merck KGaA Description, Business Overview and Total Revenue11.4.3 Merck KGaA Sales, Revenue and Gross Margin (2015-2020)11.4.4 Merck KGaA CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.4.5 Merck KGaA Recent Development11.5 Mirus Bio LLC11.5.1 Mirus Bio LLC Corporation Information11.5.2 Mirus Bio LLC Description, Business Overview and Total Revenue11.5.3 Mirus Bio LLC Sales, Revenue and Gross Margin (2015-2020)11.5.4 Mirus Bio LLC CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.5.5 Mirus Bio LLC Recent Development11.6 Editas Medicine11.6.1 Editas Medicine Corporation Information11.6.2 Editas Medicine Description, Business Overview and Total Revenue11.6.3 Editas Medicine Sales, Revenue and Gross Margin (2015-2020)11.6.4 Editas Medicine CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.6.5 Editas Medicine Recent Development11.7 Takara Bio USA11.7.1 Takara Bio USA Corporation Information11.7.2 Takara Bio USA Description, Business Overview and Total Revenue11.7.3 Takara Bio USA Sales, Revenue and Gross Margin (2015-2020)11.7.4 Takara Bio USA CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.7.5 Takara Bio USA Recent Development11.8 Thermo Fisher Scientific11.8.1 Thermo Fisher Scientific Corporation Information11.8.2 Thermo Fisher Scientific Description, Business Overview and Total Revenue11.8.3 Thermo Fisher Scientific Sales, Revenue and Gross Margin (2015-2020)11.8.4 Thermo Fisher Scientific CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.8.5 Thermo Fisher Scientific Recent Development11.9 Horizon Discovery Group11.9.1 Horizon Discovery Group Corporation Information11.9.2 Horizon Discovery Group Description, Business Overview and Total Revenue11.9.3 Horizon Discovery Group Sales, Revenue and Gross Margin (2015-2020)11.9.4 Horizon Discovery Group CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.9.5 Horizon Discovery Group Recent Development11.10 Intellia Therapeutics11.10.1 Intellia Therapeutics Corporation Information11.10.2 Intellia Therapeutics Description, Business Overview and Total Revenue11.10.3 Intellia Therapeutics Sales, Revenue and Gross Margin (2015-2020)11.10.4 Intellia Therapeutics CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.10.5 Intellia Therapeutics Recent Development11.1 Caribou Biosciences11.1.1 Caribou Biosciences Corporation Information11.1.2 Caribou Biosciences Description, Business Overview and Total Revenue11.1.3 Caribou Biosciences Sales, Revenue and Gross Margin (2015-2020)11.1.4 Caribou Biosciences CRISPR And CRISPR-Associated (Cas) Genes Products Offered11.1.5 Caribou Biosciences Recent Development 12 Future Forecast by Regions (Countries) (2021-2026)12.1 CRISPR And CRISPR-Associated (Cas) Genes Market Estimates and Projections by Region12.1.1 Global CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast by Regions 2021-202612.1.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast by Regions 2021-202612.2 North America CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast (2021-2026)12.2.1 North America: CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast (2021-2026)12.2.2 North America: CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast (2021-2026)12.2.3 North America: CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast by Country (2021-2026)12.3 Europe CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast (2021-2026)12.3.1 Europe: CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast (2021-2026)12.3.2 Europe: CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast (2021-2026)12.3.3 Europe: CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast by Country (2021-2026)12.4 Asia Pacific CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast (2021-2026)12.4.1 Asia Pacific: CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast (2021-2026)12.4.2 Asia Pacific: CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast (2021-2026)12.4.3 Asia Pacific: CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast by Region (2021-2026)12.5 Latin America CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast (2021-2026)12.5.1 Latin America: CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast (2021-2026)12.5.2 Latin America: CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast (2021-2026)12.5.3 Latin America: CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast by Country (2021-2026)12.6 Middle East and Africa CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast (2021-2026)12.6.1 Middle East and Africa: CRISPR And CRISPR-Associated (Cas) Genes Sales Forecast (2021-2026)12.6.2 Middle East and Africa: CRISPR And CRISPR-Associated (Cas) Genes Revenue Forecast (2021-2026)12.6.3 Middle East and Africa: CRISPR And CRISPR-Associated (Cas) Genes Market Size Forecast by Country (2021-2026) 13 Market Opportunities, Challenges, Risks and Influences Factors Analysis13.1 Market Opportunities and Drivers13.2 Market Challenges13.3 Market Risks/Restraints13.4 Porters Five Forces Analysis13.5 Primary Interviews with Key CRISPR And CRISPR-Associated (Cas) Genes Players (Opinion Leaders) 14 Value Chain and Sales Channels Analysis14.1 Value Chain Analysis14.2 CRISPR And CRISPR-Associated (Cas) Genes Customers14.3 Sales Channels Analysis14.3.1 Sales Channels14.3.2 Distributors 15 Research Findings and Conclusion 16 Appendix16.1 Research Methodology16.1.1 Methodology/Research Approach16.1.2 Data Source16.2 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become a brand of quality assurance in the consulting industry.

See more here:
CRISPR And CRISPR-Associated (Cas) Genes Market which company is the market leader and how much its sales in 2020 and what it's expected sales for the...

Scientists at the Council of Scientific & Industrial Research-Institute of Genomics and Integrative Biology have come up with a low-cost coronavirus test that will not require any expensive machines for detection of the pathogen.

The test can detect the coronavirus disease (Covid-19) within one hour and is expected to be available for the first phase of testing in four weeks.

Named after ''Feluda'', the detective character in legendary filmmaker Satyajit Ray's stories, although it is also an acronym for FNCAS9 Editor-Linked Uniform Detection Assay.

The test uses CRISPR gene-editing technology to identify and target the genetic material of Sars-CoV2, the virus that causes Covid-19. The test has been developed by Debojyoti Chakraborty and Souvik Maiti as a simpler way of detecting SARS-coV2 presence in clinical samples.

The CRISPR-based Feluda testing works by combining CRISPR biology and paper strip chemistry. Briefly, Cas9 protein, a component of the CRISPR system, is barcoded to interact specifically with the Sars-CoV2 sequence in the patients genetic material.

The complex of Cas9 with Sars-CoV2 is then applied to a paper strip, where using two lines (one control, one test) make it possible to determine if the test sample was infected with Covid-19.

Using the innovative chemistry on a paper strip, the CRISPR complex, bound to that specific sequence, can be visualised as a positive band, like one sees in simple pregnancy tests. The entire diagnostic process takes about one hour, starting from RNA to giving a visual readout on the strip.

Most labs are working with PCR(polymerase chain reaction)-based technology, which is costly and needs a lab set-up. The paper strip does not require (biosafety) Level-2 or Level-3 lab for testing and can be done in any path lab.

Unlike other CRISPRtests that use CAS12 and CAS13 proteins to detect Sars-CoV2, the CSIR-IGIB kit technology uses CAS9 protein (CRISPR-associated protein 9) to identify and bind to the target sequence.

CRISPR, which is short for Clustered Regularly Interspaced Short Palindromic Repeats, is a gene-editing technology that can be used to detect a specific snippet of DNA from a sequence. It can also be used to turn genes on or off without altering their sequence.

Feluda is not limited to Covid-19. The team has been working on Feluda for the past two years to develop an assay that can work on detecting any DNA-RNA or their mutations.

This is the only Covid-19 testing kit that has been developed using CRISPR-based technology in India. Feluda has been licenced to Tata Sons, which will commercialise the technology for Covid-19 detection.

Each Feluda test costs Rs 500 in the lab, and is expected to bring the cost of testing down from the Rs 4,500 per test for the real-time polymerase chain reaction test (RT-PCR), which is the only available test for detecting current Covid-19 infection.

Follow this link:
This Test Named After Satyajit Ray's Detective Character Can Reportedly Detect The Virus In An Hour - ScoopWhoop

In recent years it has become clear that a persons genetic makeup has a strong influence on body weight and how they respond to different foods and exercises.

With scientific advances, information in DNA can be used to predict which diets, lifestyle choices and exercise work best for each individual person.

Aoife Ni Eochaidh, gene tester, offers a simple, saliva-based test for men and women which analyses over 110 genetic variations that influence how persons respond to diet and exercise. These genes have been selected based on hundreds of studies.

Each test report comes with a comprehensive guide that includes a user friendly index of your DNA analysis and detailed nutritional, lifestyle and exercise recommendations. This test is a powerful tool that enables Aoife to guide you on your path to an optimal diet, lifestyle and exercise choices. Whether you are looking to lose weight, get fitter or improve your health and diet in the most optimum way for you, let your Genes predict the best options.

Further information please contact Aoife on 087 2863013 or email [emailprotected].

Continued here:
Personalise your health and fitness with genetic testing - Galway Advertiser

Progenesis

Preimplantation Genetic Testing Market Competitive Analysis:

In addition, the projections offered in this report were derived using proven research assumptions and methods. In this way, the Preimplantation Genetic Testing research study offers a collection of information and analysis for every facet of the Preimplantation Genetic Testing market such as technology, regional markets, applications and types. The Preimplantation Genetic Testing market report also offers some market presentations and illustrations that include pie charts, diagrams and charts that show the percentage of different strategies implemented by service providers in the Preimplantation Genetic Testing market. In addition, the report was created using complete surveys, primary research interviews, observations and secondary research.

In addition, the Preimplantation Genetic Testing market report introduced the market through various factors such as classifications, definitions, market overview, product specifications, cost structures, manufacturing processes, raw materials and applications. This report also provides key data on SWOT analysis, return data for investments and feasibility analysis for investments. The Preimplantation Genetic Testing market study also highlights the extremely lucrative market opportunities that are influencing the growth of the global market. In addition, the study offers a complete analysis of market size, segmentation and market share. In addition, the Preimplantation Genetic Testing report contains market dynamics such as market restrictions, growth drivers, opportunities, service providers, stakeholders, investors, important market participants, profile assessment and challenges of the global market.

Preimplantation Genetic Testing Market Segments:

The report also underscores their strategics planning including mergers, acquisitions, ventures, partnerships, product launches, and brand developments. Additionally, the report renders the exhaustive analysis of crucial market segments, which includes Preimplantation Genetic Testing types, applications, and regions. The segmentation sections cover analytical and forecast details of each segment based on their profitability, global demand, current revue, and development prospects. The report further scrutinizes diverse regions including North America, Asia Pacific, Europe, Middle East, and Africa, and South America. The report eventually helps clients in driving their Preimplantation Genetic Testing business wisely and building superior strategies for their Preimplantation Genetic Testing businesses.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24037&utm_source=COD&utm_medium=003

Table of Content

1 Introduction of Preimplantation Genetic Testing Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Preimplantation Genetic Testing Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Preimplantation Genetic Testing Market, By Deployment Model

5.1 Overview

6 Preimplantation Genetic Testing Market, By Solution

6.1 Overview

7 Preimplantation Genetic Testing Market, By Vertical

7.1 Overview

8 Preimplantation Genetic Testing Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Preimplantation Genetic Testing Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get Complete Report @ https://www.verifiedmarketresearch.com/product/Preimplantation-Genetic-Testing-Market/?utm_source=COD&utm_medium=003

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defence, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & construction, Agriculture industry and Medical Devices from over 100 countries.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

Tags: Preimplantation Genetic Testing Market Size, Preimplantation Genetic Testing Market Trends, Preimplantation Genetic Testing Market Growth, Preimplantation Genetic Testing Market Forecast, Preimplantation Genetic Testing Market Analysis NMK, Majhi Naukri, Sarkari Naukri, Sarkari Result

Our Trending Reports

Cellular Health Screening-Health Testing Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Preimplantation Genetic Testing Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

See the original post:
Preimplantation Genetic Testing Market Research Report 2020 By Size, Share, Trends, Analysis and Forecast to 2026 - Cole of Duty